US20080125857A1 - Hemocompatible polymers on hydrophobic porous polymers - Google Patents
Hemocompatible polymers on hydrophobic porous polymers Download PDFInfo
- Publication number
- US20080125857A1 US20080125857A1 US12/021,195 US2119508A US2008125857A1 US 20080125857 A1 US20080125857 A1 US 20080125857A1 US 2119508 A US2119508 A US 2119508A US 2008125857 A1 US2008125857 A1 US 2008125857A1
- Authority
- US
- United States
- Prior art keywords
- porous
- medical device
- polymer substrate
- hemocompatible
- hydrophobic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
Definitions
- the present invention relates to the field of hemocompatible polymers on hydrophobic porous polymeric materials and, in particular, to hemocompatible substances based upon complexes of heparin deposited upon porous hydrophobic polymers, typically expanded PTFE.
- blood-contacting medical devices are used internally in the treatment of the patient, implanted into the patient for an indefinite or extended period of time or inserted into the patient for relatively brief periods.
- the materials comprising the blood-contacting portions of the invasive device lack sufficient-biocompatibility and/or hemocompatibility. This tends to cause changes harmful to the patient in the blood or other fluid coming into contact with the surface (or surfaces) of the device. In such cases it is desirable to coat the surfaces of these devices with materials to enhance the biocompatibility and/or hemocompatibility.
- Invasive devices that are typically coated with biocompatible or therapeutic substances include implantable artificial orthopedic devices, dental implants, intravascular catheters, emboli capturing systems, epicardial immobilization devices, grafts, stents, intraluminal prosthetic devices and artificial heart valves, among others.
- extra-corporal medical devices that come into contact with blood in which blood is transported and/or processed external to the patient.
- a few representative examples include cardiopulmonary bypass devices, kidney dialysis equipment, blood oxygenators, separators and defoaming devices, among others.
- the blood or other bodily fluid may be reintroduced into the patient, transported for storage and/or introduced into another patient.
- the surface or the surfaces of the invasive or extra-corporal medical device be coated with substances having therapeutic functions, wherein the coatings may serve several functions in addition to increasing the biocompatibility/hemocompatibility of the surface.
- additional functions include the release of one or more therapeutic agents into the blood in appropriate dosages with appropriate timed-released characteristics and at the proper location within the patient.
- the medical device may serve as a convenient delivery platform for the delivery of therapeutically beneficial drugs in addition to its other functions.
- endoluminal stents particularly as occurring in connection with percutaneous transluminal angioplasty (“PCTA”).
- PCTA percutaneous transluminal angioplasty
- the lumen of the just-expanded vessel may contract due to several causes.
- An initial rebound of the walls of the vessel may occur following removal of the balloon.
- Further thrombosis or restenosis of the blood vessel may occur over time following the angioplasty procedure.
- Endoluminal stents have been in use for several years in conjunction with a surgical procedure inserting a tube or stent into the vessel following the PCTA procedure to assist in retaining the desired intraluminal opening.
- Heparin is an anticoagulant drug composed of a highly sulfated polysaccharide, the principle constituent of which is a glycosaminoglycan. In combination with a protein cofactor, heparin acts as an antithrombin (among other medical effects as described, for example, in Heparin - Binding Proteins, by H. B. Conrad (Academic Press, 1998)). Heparin is an attractive additive to coat on the surface(s) of blood-contacting devices in order to increase the hemocompatibility of the material and/or to release heparin or heparin complexes into the blood to combat thrombosis and restenosis.
- the heparin molecule contains numerous hydrophilic groups including hydroxyl, carboxyl, sulfate and sulfamino making underivatized heparin difficult to coat onto hydrophobic polymers.
- hydrophobic counter ions many types of complexes of heparin with hydrophobic counter ions have been used in order to increase the ability of the heparin-counter ion complex to bind to hydrophobic surfaces.
- Such counter ions are typically cationic to facilitate binding with anionic heparin, and contain a hydrophobic region to facilitate bonding with the hydrophobic polymer.
- Typical heparin complexes include, but are not limited to, heparin complex with typically large quaternary ammonium species such as benzylalkonium groups (typically introduced in the form of benzylalkonium chloride), tridodecylmethylammonium chloride (“TDMEC”), and the commercial heparin complex offered by Baxter International under the tradename DURAFLO or DURAFLO II.
- heparin complex any complex of heparin with a hydrophobic counter ion, typically a relatively large counter ion. Examples of heparin complexes are described in the following U.S. Pat. Nos. (incorporated herein by reference): 4,654,327; 4,871,357; 5,047,020; 5,069,899; 5,525,348; 5,541,167 and references cited therein.
- Implantable medical devices often require some degree of porosity to enable blood to come into contact with underlying tissues, to increase the surface area for delivery of therapeutic substances, or for other purposes. Therefore, porous polymers are widely used in medical devices.
- the advantages of porosity are not limited to implantable devices, and porous materials are used in extra-corporal devices as well as invasive medical devices.
- the problem of coating with heparin is exacerbated if the hydrophobic polymer is also porous. In addition to binding with the hydrophobic surface, the heparin complex must also penetrate into the interstices of the porous structure of the polymer and bind to all or substantially all of the polymer surface that comes into contact with blood.
- Fluorinated polymers are typically chemically unreactive, have low surface energy and are hydrophobic. Such properties are generally favorable for use in medical devices as described, for example by F. H. Silver and D. L. Christiansen in Biomaterials Science and Biocompatibility, (Springer-Verlag, 1999) p. 19.
- Poly(tetrafluoroethylene), PTFE is a polymeric material with repeating units of (—CF 2 CF 2 —) having numerous commercial uses, including in blood-contacting devices, due in large part to its chemical inertness and desirable physical properties.
- PTFE in the form of a film or solid has low surface energy and, therefore, is a relatively difficult surface to coat (or “wet”).
- “Wetting” typically indicates the tendency of a liquid to spread and coat the surface onto which it is placed.
- the specific relationship between surface energy and the contact angle at the interface between a drop and the surface is given in standard references including Physical Chemistry of Surfaces 6 th Ed. by A. W. Adams and A. P. Gast (John Wiley, 1997), p. 465 ff.
- a contact angle between the liquid and the surface greater than approximately 90° typically indicates a non-wetting liquid on that particular surface.
- Expanded PTFE is a form of PTFE that has been physically expanded along one or more directions to create a porous form of PTFE having varying amounts of porosity depending on several factors including the specific procedures for performing the mechanical expansion.
- the porous ePTFE thus created is useful for the manufacture of several commercial products as illustrated (for example) by the work of Gore in U.S. Pat. Nos. 3,953,566 and 4,187,390 and the work of House et. al. in U.S. Pat. No.
- Expanded PTFE is widely used in medical devices and is perhaps one of the most widely used vascular graft materials.
- ePTFE has a large range of application in blood-contacting medical devices including, but not limited to, segmental venous replacements, reconstructed veins in organ transplantation, polymer catheters, in-dwelling catheters, urological and coronary stents, covered stents, heart valves, dental implants, orthopedic devices, vascular grafts, synthetic by-pass grafts and other invasive and implantable medical devices.
- ePTFE can be used in extra-corporal blood-contacting devices. Examples include, but are not limited to, heart by-pass devices, kidney dialysis equipment, blood oxygenators, defoaming machines, among others.
- FIG. 1 is a scanning electron micrograph of porous ePTFE from the work of House et. al. (U.S. Pat. No. 6,048,484).
- FIGS. 2A and 2B are schematic depictions of two forms of ePTFE showing biaxially oriented fibrils ( FIG. 2A ), and multiaxially oriented fibrils ( FIG. 2B ). Both FIGS. 2A and 2B are from House et. al. (supra).
- ePTFE tends to be thrombogenic and its porosity may release entrapped gases (which may itself be a source of thrombogenicity as discussed, for example, by Vaun et. al. U.S. Pat. No. 5,181,903). Therefore, considerable effort has gone into the coating of ePTFE to reduce its thrombogenicity and/or provide other therapeutic effects.
- Hemocompatibility can be achieved by a variety of means, including coating with a hydrophilic, biologically passive, polymer, or by coating with materials having a biologically active component such as heparin or a complex of heparin including the commercially available heparin complex DURAFLO or DURAFLO II (Baxter Healthcare, Inc.).
- a biologically active component such as heparin or a complex of heparin including the commercially available heparin complex DURAFLO or DURAFLO II (Baxter Healthcare, Inc.).
- Improved procedures for coating ePTFE with hemocompatible substances, typically substances containing derivatives or complexes of heparin, and the improved hemocompatible materials so produced are among the objects of the present invention.
- PET polyethylene terephthalates
- PTFE is but one example of the general chemical class of fluoropolymer that also includes FEP (fluorinated ethylene propylene), PFA (perfluoroalkyl vinyl ether and tetrafluoroethylene co-polymer), PVDF (polyvinylidenedifluoride), PVF (polyvinylfluoride), PCTFE (polychlorotrifluoroethylene), ETFE (ethylene and tetrafluoroethylene co-polymer) TFB (terpolymer of vinylidenedifluoride, hexafluoropropylene and tetrafluoroethylene) and other fluoropolymers as known in the art and described in many references including, for example, W. Woebcken in Saechtling International Plastics Handbook for the Technologist Engineer and User, 3 rd Ed., (Hanser Publishers, 1995) pp. 234-240, incorporated herein by reference.
- FEP fluorinated ethylene propylene
- PFA per
- Coating the interior regions of highly porous materials such as ePTFE with significant amounts of a hemocompatible substances presents special challenges in addition to the hydrophobicity, deriving in part from the relative inaccessibility of much of the surface to be coated.
- a medical device comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate.
- the hemocompatible polymer substrate is produced by a method comprising the following acts: a) providing a hemocompatible substance, b) preparing a solution comprising a mixture of: a first solvent that wets the porous hydrophobic polymer substrate; a second solvent that enhances the solubility of the hemocompatible substance in the solution; and the hemocompatible substance; and, c)contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer substrate, provided that the hemocompatible substance is not subjected to a dialdehyde cross-linking or dialdehyde stabilization step before in vivo use.
- a medical device comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate.
- the hemocompatible polymer substrate is produced by a method comprising the following acts: a) providing a hemocompatible substance, b) preparing a solution comprising a mixture of: a first solvent that wets the porous hydrophobic polymer substrate; a second solvent that particularly enhances the solubility of the hemocompatible substance in the solution; and the hemocompatible substance; and c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer substrate.
- a medical device comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate.
- the hemocompatible polymer substrate is produced by a method comprising the following acts: a) providing a hemocompatible substance, b) preparing a solution comprising a mixture of: a first solvent that wets the porous hydrophobic polymer substrate; a second solvent that enhances the solubility of the hemocompatible substance in the solution; and the hemocompatible substance; and c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer, provided that the amount of a mixture of trichloro trifluoro ethanes is 10 wt % or less.
- a medical device comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate.
- the hemocompatible polymer substrate is produced by a method comprising the following acts: a) providing a hemocompatible substance, b) preparing a solution comprising a mixture of: a first solvent that wets the porous hydrophobic polymer substrate; a second solvent that enhances the solubility of the hemocompatible substance in the solution; and the hemocompatible substance; and c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer substrate, provided that the solution has a maximum ethanol content of 10 wt %.
- An example of the medican device of the above various embodiments is a stent.
- the second solvent particularly enhances solubility of the hemocompatible substance.
- the porous hydrophobic polymer substrate can compose a blood-contacting component of a medical device.
- the porous hydrophobic polymer substrate can include at least one polymer material such as porous polyethylene materials, porous polypropylene materials, porous polyurethane materials, porous polyacrylate materials, porous polymethacrylate materials and porous fluoropolymer materials.
- the porous fluoropolymer material comprises an expanded poly(tetrafluoroethylene) material.
- the hemocompatible substance can comprise ionic heparin and a hydrophobic counter ion.
- the hydrophobic counter ion can be a hydrophobic quaternary ammonium ion.
- the hydrophobic counter ion can one or more of benzylalkonium ion and tridodecylmethylammonium ion.
- the hemocompatible substance can form a coating on the porous hydrophobic polymer substrate.
- the hemocompatible substance can be deposited on the porous hydrophobic polymer substrate by dipping.
- FIG. 1 Scanning electron micrograph of ePTFE from U.S. Pat. No. 6,048,484.
- FIG. 2A Schematic depiction of porous structure of ePTFE from U.S. Pat. No. 6,048,484 depicting biaxially oriented fibrils.
- FIG. 2B Schematic depiction of porous structure of ePTFE from U.S. Pat. No. 6,048,484 depicting multiaxially oriented fibrils.
- FIG. 3 Cut-away depiction of a portion of a covered stent.
- the present invention relates to the coating of porous, hydrophobic polymers, typically fluoropolymers such as expanded poly(tetrafluoroethylene), ePTFE, with hemocompatible substances, so as to perfuse and coat substantially all regions of the surface that come into contact with blood, including the interior regions of the porous structure that are difficult to access and difficult to coat by conventional means.
- porous, hydrophobic polymers typically fluoropolymers such as expanded poly(tetrafluoroethylene), ePTFE
- hemocompatible substances so as to perfuse and coat substantially all regions of the surface that come into contact with blood, including the interior regions of the porous structure that are difficult to access and difficult to coat by conventional means.
- Complexes of heparin are the typical hemocompatible substances employed in some embodiments of the present invention.
- wetting indicates that the contact angle formed by the tangent to the surface of the liquid and the surface of the solid at the point of contact is less than 90° (measured through the liquid phase) such that the liquid tends to spread over the surface of the solid. Conversely, nonwetting indicates that the liquid tends to ball up on the surface of the solid and run off the surface easily.
- Contact angles are known in the art and provide one criteria by which candidate solvents of the present invention can be identified. For example, contact angles of selected liquids with selected surfaces (including fluoropolymers such as PTFE, FEP) are provided in Physical Chemistry of Surfaces 6 th Ed. (supra) pp. 365-366.
- the present invention is not inherently limited to ePTFE or to fluoropolymers as a class.
- Porous hydrophobic polymeric materials that are typically difficult to coat with hemocompatible materials by procedures of the prior art are included within the scope of the present invention.
- porous hydrophobic polymers include the following: porous polyethylene, porous polypropylene, porous polyurethanes, porous polyacrylates, porous polymethacrylates, among others.
- Biocompatible polyurethanes, PETs and other polymers have also been used as blood-contacting substances in medical devices, subject to coating with heparin complexes and/or other hemocompatible or therapeutic molecules pursuant to the methods of the present invention.
- PTFE is but one example of a class of commercially important fluoropolymers.
- Blends containing ePTFE, other fluoropolymers and/or other hydrophobic polymers are included within the scope of the present invention. Such blends are coatable by means of the procedures described herein and the resulting coated materials are useful in blood-contacting medical devices.
- the present invention relates to coating ePTFE without distinction as to the particular microstructure present in the ePTFE prior to coating.
- ePTFE to indicate any porous structure of the PTFE polymer, irrespective of its specific and detailed microstructure and irrespective of the detailed procedure for its formation.
- Commercially available embodiments of ePTFE such as GORE-TEX (W. L. Gore and Associates) are included.
- mechanically expansion of PTFE is the means by which porosity is obtained.
- Gore U.S. Pat. Nos. 3,953,566 and 4,187,390, incorporated herein by reference
- mechanical expansion is not the only way to obtain porous PTFE.
- the coating procedures of the present invention can be used for coating porous polymeric materials, including ePTFE, irrespective of the specific mechanism by which the porosity is introduced into the material.
- ePTFE porous form of PTFE, however produced, recognizing that mechanically expanded PTFE is but one means of obtaining the desired porosity.
- Liquids having contact angles with PTFE less than 90° include non-polar organic solvents such as alkanes (pentane, hexane, heptane and octane, among others) and cycloalkanes, freons or related materials such as chlorofluorocarbons (“CFCs”) and hydrochlorofluorocarbons (“HCFCs”).
- CFCs chlorofluorocarbons
- HCFCs hydrochlorofluorocarbons
- Commercial solvents include CFCs and HCFCs such as “Techspray AMS Flux Remover” (from Techspray, Inc., of Amarillo, Tex.) and “Gensolv 2004” (from Micro Care Corp. of Bristol, Conn.).
- a candidate solvent is any solvent that is known to wet fluoropolymers (particularly ePTFE) or the hydrophobic polymer of interest. Although pure solvents are discussed herein, this is merely for economy of language. Mixtures of solvents that retain the property of being able to wet the hydrophobic surface, particularly ePTFE, are included within the scope of the present invention.
- Some invention embodiments specifically exclude solvent mixtures that comprise more than 10 weight percent, more than 20 weight percent, more than 30 weight percent, or more than 40 weight percent of a mixture of trifluoro trichloro ethanes.
- a hydrophobic complex of heparin is dissolved in the polymer-wetting primary solvent for penetration into the porous structure and deposition onto ePTFE in some embodiments of the present invention.
- Some (typically small) amount of heparin complex dissolves in pure polymer-wetting solvent as described above, but typically does not lead to biologically useful amounts of heparin being deposited onto the hydrophobic surfaces. Therefore, in some embodiments of the present invention, the solubility of heparin complexes is enhanced by the addition of relatively small amounts of a polar solvent to the non-polar primary solvent.
- the non-polar primary solvent is chosen to provide adequate penetration into the interior of the porous hydrophobic material, while the polar solubility-enhancing component of the solvent is selected to facilitate dissolution of heparin complexes in the solvent mixture.
- polar solubility-enhancing additives included organic alcohols (methanol, ethanol, among others), ketones (acetone, methylethylketone, among others). Mixtures of one or more chemical compounds can also be used as the solubility-enhancing solvent.
- the solubility-enhancing component is limited to solvents or solvent mixtures that have at least the following two characteristics.
- the hemocompatible substance is more soluble in the solubility-enhancing component than the substance is in the polymer-wetting primary solvent.
- the hemocompatible substance is more soluble in the solubility-enhancing component than it is in a mixture of the polymer-wetting primary solvent and the solubility-enhancing component.
- Such solubility-enhancing components are said to be particularly solubility enhancing.
- Some invention embodiments specifically exclude solvent mixtures that comprise more than 1 weight percent, more than 2 weight percent, more than 3 weight percent, more than 4 weight percent, more than 5 weight percent, more than 10 weight percent, more than 20 weight percent, more than 30 weight percent, or more than 40 weight percent of ethanol.
- the polar solvent be added to the non-polar solvent in an amount so as to form an azeotropic mixture.
- Azeotropic mixtures have the property of evaporating such that the unevaporated liquid retains the same composition to dryness.
- non-azeotropic mixtures typically become more concentrated in the less volatile solvent as evaporation proceeds. A solute will thus experience a changing solvent composition during evaporation for non-azeotropic mixtures. This may lead to precipitation of the solute and tend to create non-uniform coatings.
- non-azeotropic mixtures may be used with acceptable results, azeotropic mixtures typically give better coatings.
- HCFC-225 is a mixture of isomers of dichloropentafluoropropane, typically HCFC-225ca is CF 3 CF 2 CHCl 2 and HCFC225cb is CCIF 2 CF 2 CHFCl.
- azeotropic mixtures are not necessary in the present invention and adequate results are obtained with concentrations of polar solvent from approximately 0.00001% up to saturation of the polar solvent dissolved in the non-polar solvent.
- concentrations of polar solvent in the range from about 0.1% to about 10% by volume are used.
- concentrations in the range from approximately 0.1% to approximately 2% are particularly useful in that 0.5% has enough hemocompatible material for therapeutically effective coatings by 1% is dilute enough to avoid webbing.
- the present invention includes adding relatively small amounts of an organic alcohol (such as ethanol, methanol, among others) or a similar solubility-enhancing polar solvent to a polymer-wetting solvent.
- the solubility enhancing solvent is added to the polymer-wetting solvent in such quantity (typically small) that the mixed solvent provides adequate solubility for heparin complexes without substantially hindering penetration of the pores or wetting of the hydrophobic polymer.
- a mixed solvent is created that both wets ePTFE and delivers heparin to all surfaces of the porous structure.
- coating of the ePTFE with the heparin complex may be performed by any convenient method that brings the heparin-containing solution into intimate contact with all surface regions of the ePTFE substrate including the interior regions of the pores.
- Dip coating is one technique that can be used in some embodiments of the present invention although other coating techniques known in the art may also be used, including spraying.
- FIG. 3 depicts a portion of an endoluminal stent in cut-away view, showing the interior region of the stent, 1 , the struts, 2 , and a covering, 3 .
- the covering material for the stent, 3 is typically porous to allow blood flowing on the interior of the stent, 1 , to come into contact with the interior surfaces of the lumen in which the stent is placed. Porous materials containing hemocompatible substances thereon may be used in many medical devices, one example of which is stent covering, 3 . Expanded PTFE is a typical stent covering material. Other materials for covering stents are described elsewhere herein and in the references cited.
- Hemocompatible substances placed onto stent cover, 3 include heparin and heparin complexes.
- One embodiment of the present invention relates to coating a ePTFE stent covering material with a heparin complex, typically DURAFLO or DURAFLO II.
- Typical pore sizes of ePTFE are in the range of approximately 5 ⁇ m (microns) to approximately 200 ⁇ m, commonly in the range from approximately 40 ⁇ m to approximately 120 ⁇ m.
- DURAFLO II may be used herein in place of DURAFLO without modification.
- the material produced by the above procedure is a suitable stent covering material containing DURAFLO (or other heparin complex) coated on substantially all surfaces thereof that will be exposed to blood during use. Dip or spray coating is conveniently done on a porous, hydrophobic polymer already mounted on the struts, forming thereby a stent covering.
- the hydrophobic, porous material may be coated pursuant to the present invention before, during or following the fabrication of the material into a medical device. The timing of coating and device fabrication is determined in part by manufacturing considerations including the damage likely to result to the hemocompatible substance by processing during device fabrication.
- the properties of the coating can be tested in vitro by standard testing methods including AT-III binding or anti-Factor Xa Assay. Other biological assays include various ex vivo shunts.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
Various embodiments of the present invention provide a medical device comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate. One embodiment of the present invention relates to the providing of expanded poly(tetrafluoroethylene) with one or more complexes of heparin, typically containing heparin in combination with a hydrophobic counter ion. The hemocompatible substance is dissolved in a mixture of solvents in which a first solvent wets the polymer substrate to be coated and the second solvent enhances the solubility of the hemocompatible substance material in the solvent mixture. Typical first solvents wetting a hydrophobic polymer substrate include non-polar such as hydrocholorofluorocarbons. Typical second solvents include polar solvents such as organic alcohols and ketones. Azeotropic mixtures of the second solvent in the first solvent are used in some embodiments of the present invention although second solvents may be employed in a range of concentration ranges from less than 0.1% up to saturation.
Description
- This application is a divisional application of U.S. application Ser. No. 10/818,927, filed Apr. 5, 2004, which is a Continuing-in-Part application from U.S. application Ser. No. 09/704,212, filed 31 Oct. 2000, issued as U.S. Pat. No. 6,833,153, the teachings of which are incorporated herein by reference in their entirety.
- 1. Field of the Invention
- The present invention relates to the field of hemocompatible polymers on hydrophobic porous polymeric materials and, in particular, to hemocompatible substances based upon complexes of heparin deposited upon porous hydrophobic polymers, typically expanded PTFE.
- 2. Description of Related Art
- Continuing advances in medical technology have led to the development and use of numerous medical devices that come into contact with blood or other bodily fluids. To be concrete in our discussion, we focus herein on the particular example of medical devices coming into contact with mammalian blood, particularly human blood, not intending thereby to limit the scope of the present invention to medical devices used exclusively on human patients. In using such devices, it is important that contact of the blood or other bodily fluid with the various components of the medical device not cause therapeutically detrimental alterations to the fluid. In many cases, it is desirable to coat such devices with materials to enhance the biocompatiblity of the devices, including coatings that contain bioactive agents, anticoagulants, antimicrobial agents or a variety of other drugs.
- It is convenient to consider blood-contacting medical devices as invasive or extra-corporal, although some devices span both classes. Invasive devices are used internally in the treatment of the patient, implanted into the patient for an indefinite or extended period of time or inserted into the patient for relatively brief periods. In many cases, the materials comprising the blood-contacting portions of the invasive device lack sufficient-biocompatibility and/or hemocompatibility. This tends to cause changes harmful to the patient in the blood or other fluid coming into contact with the surface (or surfaces) of the device. In such cases it is desirable to coat the surfaces of these devices with materials to enhance the biocompatibility and/or hemocompatibility. Invasive devices that are typically coated with biocompatible or therapeutic substances include implantable artificial orthopedic devices, dental implants, intravascular catheters, emboli capturing systems, epicardial immobilization devices, grafts, stents, intraluminal prosthetic devices and artificial heart valves, among others.
- There are also many examples of extra-corporal medical devices that come into contact with blood in which blood is transported and/or processed external to the patient. A few representative examples include cardiopulmonary bypass devices, kidney dialysis equipment, blood oxygenators, separators and defoaming devices, among others. Following such extra-corporal processing, the blood or other bodily fluid may be reintroduced into the patient, transported for storage and/or introduced into another patient. In using such extra-corporal devices, it is important that contact of the blood or other bodily fluid with the various components of the device not cause therapeutically detrimental alterations to the fluid.
- It is important in some cases that the surface or the surfaces of the invasive or extra-corporal medical device be coated with substances having therapeutic functions, wherein the coatings may serve several functions in addition to increasing the biocompatibility/hemocompatibility of the surface. Examples of such additional functions include the release of one or more therapeutic agents into the blood in appropriate dosages with appropriate timed-released characteristics and at the proper location within the patient. Thus, the medical device may serve as a convenient delivery platform for the delivery of therapeutically beneficial drugs in addition to its other functions.
- One important application related to implantable devices arises in connection with endoluminal stents, particularly as occurring in connection with percutaneous transluminal angioplasty (“PCTA”). Following balloon angioplasty, the lumen of the just-expanded vessel may contract due to several causes. An initial rebound of the walls of the vessel may occur following removal of the balloon. Further thrombosis or restenosis of the blood vessel may occur over time following the angioplasty procedure. The result is often the necessity for another angioplasty procedure or surgical by-pass. Endoluminal stents have been in use for several years in conjunction with a surgical procedure inserting a tube or stent into the vessel following the PCTA procedure to assist in retaining the desired intraluminal opening. A review of the procedure may be found in Endoluminal Stenting by Ulrich Sigwart, Ed. (W. B. Saunders, 1996). A compendium of coronary stents is given in Handbook of Coronary Stents, 3rd Ed. by P. W. Serruys and M. JB Kutryk, Eds. (Martin Dunitz Ltd., 2000). However, even with stenting, occlusions frequently recur within the stent requiring further PCTA or by-pass surgery. Such restenosis following PCTA and the insertion of a stent is sought to be prevented by the use of coated stents. Coatings on stents are often used for the delivery of anticoagulants or other medication that assist in preventing thrombosis and restenosis.
- Heparin is an anticoagulant drug composed of a highly sulfated polysaccharide, the principle constituent of which is a glycosaminoglycan. In combination with a protein cofactor, heparin acts as an antithrombin (among other medical effects as described, for example, in Heparin-Binding Proteins, by H. B. Conrad (Academic Press, 1998)). Heparin is an attractive additive to coat on the surface(s) of blood-contacting devices in order to increase the hemocompatibility of the material and/or to release heparin or heparin complexes into the blood to combat thrombosis and restenosis.
- The heparin molecule contains numerous hydrophilic groups including hydroxyl, carboxyl, sulfate and sulfamino making underivatized heparin difficult to coat onto hydrophobic polymers. Thus, many types of complexes of heparin with hydrophobic counter ions have been used in order to increase the ability of the heparin-counter ion complex to bind to hydrophobic surfaces. Such counter ions are typically cationic to facilitate binding with anionic heparin, and contain a hydrophobic region to facilitate bonding with the hydrophobic polymer. Typical heparin complexes include, but are not limited to, heparin complex with typically large quaternary ammonium species such as benzylalkonium groups (typically introduced in the form of benzylalkonium chloride), tridodecylmethylammonium chloride (“TDMEC”), and the commercial heparin complex offered by Baxter International under the tradename DURAFLO or DURAFLO II. Herein we denote as “heparin complex” any complex of heparin with a hydrophobic counter ion, typically a relatively large counter ion. Examples of heparin complexes are described in the following U.S. Pat. Nos. (incorporated herein by reference): 4,654,327; 4,871,357; 5,047,020; 5,069,899; 5,525,348; 5,541,167 and references cited therein.
- Considerable work has been done in developing coatings for application to various medical devices in which the coatings contain at least one form of heparin or heparin complex. Combinations of heparin and heparin complexes with other drugs, as well as various techniques for tailoring the coating to provide desired drug-release characteristics have been studied. Examples of such work include that of Chen et. al. (incorporated herein by reference), published in J. Vascular Surgery, Vol 22, No. 3 pp 237-247 (September 1995) and the following U.S. Pat. Nos. (incorporated herein by reference): 4,118,485; 4,678,468; 4,745,105; 4,745,107; 4,895,566; 5,013,717; 5,061,738; 5,135,516; 5,322,659; 5,383,927; 5,417,969; 5,441,759; 5,865,814; 5,876,433; 5,879,697; 5,993,890 as well as references cited in the foregoing patents and article, such cited references hereby incorporated a reference into this document.
- Implantable medical devices often require some degree of porosity to enable blood to come into contact with underlying tissues, to increase the surface area for delivery of therapeutic substances, or for other purposes. Therefore, porous polymers are widely used in medical devices. The advantages of porosity are not limited to implantable devices, and porous materials are used in extra-corporal devices as well as invasive medical devices. However, the problem of coating with heparin is exacerbated if the hydrophobic polymer is also porous. In addition to binding with the hydrophobic surface, the heparin complex must also penetrate into the interstices of the porous structure of the polymer and bind to all or substantially all of the polymer surface that comes into contact with blood.
- Fluorinated polymers are typically chemically unreactive, have low surface energy and are hydrophobic. Such properties are generally favorable for use in medical devices as described, for example by F. H. Silver and D. L. Christiansen in Biomaterials Science and Biocompatibility, (Springer-Verlag, 1999) p. 19. Poly(tetrafluoroethylene), PTFE, is a polymeric material with repeating units of (—CF2CF2—) having numerous commercial uses, including in blood-contacting devices, due in large part to its chemical inertness and desirable physical properties. PTFE in the form of a film or solid has low surface energy and, therefore, is a relatively difficult surface to coat (or “wet”). “Wetting” typically indicates the tendency of a liquid to spread and coat the surface onto which it is placed. The specific relationship between surface energy and the contact angle at the interface between a drop and the surface (the “wetting”) is given in standard references including Physical Chemistry of Surfaces 6th Ed. by A. W. Adams and A. P. Gast (John Wiley, 1997), p. 465 ff. A contact angle between the liquid and the surface greater than approximately 90° typically indicates a non-wetting liquid on that particular surface.
- In many medical and non-medical commercial uses, it is desirable to have PTFE in the form of a porous film that retains adequate physical strength for the particular application while not substantially increasing the cost of the material. Expanded PTFE (hereinafter “ePTFE”) is a form of PTFE that has been physically expanded along one or more directions to create a porous form of PTFE having varying amounts of porosity depending on several factors including the specific procedures for performing the mechanical expansion. The porous ePTFE thus created is useful for the manufacture of several commercial products as illustrated (for example) by the work of Gore in U.S. Pat. Nos. 3,953,566 and 4,187,390 and the work of House et. al. in U.S. Pat. No. 6,048,484.Applications to stents include the work of Lewis et. al. (U.S. Pat. No. 5,993,489) and Bley et. al. (U.S. Pat. Nos. 5,674,241 and 5,968,070). The chemical inactivity, and other properties of fluorinated polymers including PTPE and ePTFE, have made them attractive substances for use in many medical and blood-contacting devices. Representative examples include dental implant devices (Scantlebury et. al. U.S. Pat. No. 4,531,916), grafts, stents and intraluminal prosthetic devices (Bley et. al. U.S. Pat. Nos. 5,674,241 and 5,968,070; Goldfarb et. al. U.S. Pat. No. 5,955,016; Lewis et. al. U.S. Pat. No. 5,993,489; Tu et. al. U.S. Pat. No. 6,090,134).
- Expanded PTFE is widely used in medical devices and is perhaps one of the most widely used vascular graft materials. In fact, ePTFE has a large range of application in blood-contacting medical devices including, but not limited to, segmental venous replacements, reconstructed veins in organ transplantation, polymer catheters, in-dwelling catheters, urological and coronary stents, covered stents, heart valves, dental implants, orthopedic devices, vascular grafts, synthetic by-pass grafts and other invasive and implantable medical devices. In addition, ePTFE can be used in extra-corporal blood-contacting devices. Examples include, but are not limited to, heart by-pass devices, kidney dialysis equipment, blood oxygenators, defoaming machines, among others.
-
FIG. 1 is a scanning electron micrograph of porous ePTFE from the work of House et. al. (U.S. Pat. No. 6,048,484).FIGS. 2A and 2B are schematic depictions of two forms of ePTFE showing biaxially oriented fibrils (FIG. 2A ), and multiaxially oriented fibrils (FIG. 2B ). BothFIGS. 2A and 2B are from House et. al. (supra). Low surface energy characteristic of fluoropolymers and other hydrophobic polymers, in combination with the porosity of ePTFE, make the application of a coating to ePTFE, including coating of the interior surfaces of the pores, a significant challenge. Providing such a coating for ePTFE is one objective of the present invention. - However, when used in a blood-contacting environment, ePTFE tends to be thrombogenic and its porosity may release entrapped gases (which may itself be a source of thrombogenicity as discussed, for example, by Vaun et. al. U.S. Pat. No. 5,181,903). Therefore, considerable effort has gone into the coating of ePTFE to reduce its thrombogenicity and/or provide other therapeutic effects. Hemocompatibility can be achieved by a variety of means, including coating with a hydrophilic, biologically passive, polymer, or by coating with materials having a biologically active component such as heparin or a complex of heparin including the commercially available heparin complex DURAFLO or DURAFLO II (Baxter Healthcare, Inc.). Improved procedures for coating ePTFE with hemocompatible substances, typically substances containing derivatives or complexes of heparin, and the improved hemocompatible materials so produced are among the objects of the present invention. We use the expressions “derivative of heparin” and “complex of heparin” interchangeably herein without distinction to indicate a chemical combination of heparin with a counter ion.
- Although fluoropolymers have been among the most commonly used materials for blood-contacting devices, polyurethanes, polyethylene terephthalates (“PETs”) and numerous other fluorinated and non-fluorinated polymers have also found considerable application. Modifications of polyurethanes, PETs and other plastics have included the introduction of coatings for antithrombogenic and anticoagulant properties. PET is an example of a non-fluorinated polymer that is highly hydrophobic and therefore difficult to coat with polar, aqueous materials such as heparin. PTFE is but one example of the general chemical class of fluoropolymer that also includes FEP (fluorinated ethylene propylene), PFA (perfluoroalkyl vinyl ether and tetrafluoroethylene co-polymer), PVDF (polyvinylidenedifluoride), PVF (polyvinylfluoride), PCTFE (polychlorotrifluoroethylene), ETFE (ethylene and tetrafluoroethylene co-polymer) TFB (terpolymer of vinylidenedifluoride, hexafluoropropylene and tetrafluoroethylene) and other fluoropolymers as known in the art and described in many references including, for example, W. Woebcken in Saechtling International Plastics Handbook for the Technologist Engineer and User, 3rd Ed., (Hanser Publishers, 1995) pp. 234-240, incorporated herein by reference.
- Coating the interior regions of highly porous materials such as ePTFE with significant amounts of a hemocompatible substances presents special challenges in addition to the hydrophobicity, deriving in part from the relative inaccessibility of much of the surface to be coated.
- According to an embodiment of the present invention, it is provided a medical device comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate. The hemocompatible polymer substrate is produced by a method comprising the following acts: a) providing a hemocompatible substance, b) preparing a solution comprising a mixture of: a first solvent that wets the porous hydrophobic polymer substrate; a second solvent that enhances the solubility of the hemocompatible substance in the solution; and the hemocompatible substance; and, c)contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer substrate, provided that the hemocompatible substance is not subjected to a dialdehyde cross-linking or dialdehyde stabilization step before in vivo use.
- According to another embodiment of the present invention, it is provided a medical device comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate. The hemocompatible polymer substrate is produced by a method comprising the following acts: a) providing a hemocompatible substance, b) preparing a solution comprising a mixture of: a first solvent that wets the porous hydrophobic polymer substrate; a second solvent that particularly enhances the solubility of the hemocompatible substance in the solution; and the hemocompatible substance; and c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer substrate.
- According to a further embodiment of the present invention, it is provided a medical device comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate. The hemocompatible polymer substrate is produced by a method comprising the following acts: a) providing a hemocompatible substance, b) preparing a solution comprising a mixture of: a first solvent that wets the porous hydrophobic polymer substrate; a second solvent that enhances the solubility of the hemocompatible substance in the solution; and the hemocompatible substance; and c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer, provided that the amount of a mixture of trichloro trifluoro ethanes is 10 wt % or less.
- According to a further embodiment of the present invention, it is provided a medical device, comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate. The hemocompatible polymer substrate is produced by a method comprising the following acts: a) providing a hemocompatible substance, b) preparing a solution comprising a mixture of: a first solvent that wets the porous hydrophobic polymer substrate; a second solvent that enhances the solubility of the hemocompatible substance in the solution; and the hemocompatible substance; and c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer substrate, provided that the solution has a maximum ethanol content of 10 wt %.
- An example of the medican device of the above various embodiments is a stent.
- In the various embodiments above, the second solvent particularly enhances solubility of the hemocompatible substance.
- In the various embodiments above, the porous hydrophobic polymer substrate can compose a blood-contacting component of a medical device. The porous hydrophobic polymer substrate can include at least one polymer material such as porous polyethylene materials, porous polypropylene materials, porous polyurethane materials, porous polyacrylate materials, porous polymethacrylate materials and porous fluoropolymer materials. In some embodiments, the porous fluoropolymer material comprises an expanded poly(tetrafluoroethylene) material.
- In the various embodiments above, the hemocompatible substance can comprise ionic heparin and a hydrophobic counter ion. In some embodiments, the hydrophobic counter ion can be a hydrophobic quaternary ammonium ion. In some embodiments, the hydrophobic counter ion can one or more of benzylalkonium ion and tridodecylmethylammonium ion. In some embodiments, the hemocompatible substance can form a coating on the porous hydrophobic polymer substrate.
- In the various embodiments above, the hemocompatible substance can be deposited on the porous hydrophobic polymer substrate by dipping.
-
FIG. 1 : Scanning electron micrograph of ePTFE from U.S. Pat. No. 6,048,484. -
FIG. 2A : Schematic depiction of porous structure of ePTFE from U.S. Pat. No. 6,048,484 depicting biaxially oriented fibrils. -
FIG. 2B : Schematic depiction of porous structure of ePTFE from U.S. Pat. No. 6,048,484 depicting multiaxially oriented fibrils. -
FIG. 3 : Cut-away depiction of a portion of a covered stent. - The present invention relates to the coating of porous, hydrophobic polymers, typically fluoropolymers such as expanded poly(tetrafluoroethylene), ePTFE, with hemocompatible substances, so as to perfuse and coat substantially all regions of the surface that come into contact with blood, including the interior regions of the porous structure that are difficult to access and difficult to coat by conventional means. Complexes of heparin are the typical hemocompatible substances employed in some embodiments of the present invention.
- We follow the conventional usage that “wetting” indicates that the contact angle formed by the tangent to the surface of the liquid and the surface of the solid at the point of contact is less than 90° (measured through the liquid phase) such that the liquid tends to spread over the surface of the solid. Conversely, nonwetting indicates that the liquid tends to ball up on the surface of the solid and run off the surface easily. Contact angles are known in the art and provide one criteria by which candidate solvents of the present invention can be identified. For example, contact angles of selected liquids with selected surfaces (including fluoropolymers such as PTFE, FEP) are provided in Physical Chemistry of Surfaces 6th Ed. (supra) pp. 365-366.
- The present invention is not inherently limited to ePTFE or to fluoropolymers as a class. Porous hydrophobic polymeric materials, that are typically difficult to coat with hemocompatible materials by procedures of the prior art are included within the scope of the present invention. Examples of porous hydrophobic polymers include the following: porous polyethylene, porous polypropylene, porous polyurethanes, porous polyacrylates, porous polymethacrylates, among others. Biocompatible polyurethanes, PETs and other polymers have also been used as blood-contacting substances in medical devices, subject to coating with heparin complexes and/or other hemocompatible or therapeutic molecules pursuant to the methods of the present invention. However, PTFE is but one example of a class of commercially important fluoropolymers. Other examples include those noted above; FEP, PFA, PVDF, PVF, PCTFE, ETFE, TFB and other fluoropolymers as known in the art. Blends containing ePTFE, other fluoropolymers and/or other hydrophobic polymers are included within the scope of the present invention. Such blends are coatable by means of the procedures described herein and the resulting coated materials are useful in blood-contacting medical devices.
- To be concrete in our discussions we describe in detail the particular embodiments in which expanded PTFE is coated with a hemocompatible substance containing heparin as one component thereof. Other embodiments making use of other porous hydrophobic polymers and/or other hemocompatible substances consistent with the procedures and conditions of the present invention represent obvious modifications of the present invention and are included within its scope. Some embodiments specifically exclude subjecting the hemocompatible substance to a dialdehyde cross-linking or dialdehyde stabilization step before in vivo use.
- The present invention relates to coating ePTFE without distinction as to the particular microstructure present in the ePTFE prior to coating. Herein we use “ePTFE” to indicate any porous structure of the PTFE polymer, irrespective of its specific and detailed microstructure and irrespective of the detailed procedure for its formation. Commercially available embodiments of ePTFE such as GORE-TEX (W. L. Gore and Associates) are included. In some embodiments of the present invention, mechanically expansion of PTFE is the means by which porosity is obtained. However, as described by Gore (U.S. Pat. Nos. 3,953,566 and 4,187,390, incorporated herein by reference), mechanical expansion is not the only way to obtain porous PTFE. The coating procedures of the present invention can be used for coating porous polymeric materials, including ePTFE, irrespective of the specific mechanism by which the porosity is introduced into the material. However, for economy of language, we use “ePTFE” to denote a porous form of PTFE, however produced, recognizing that mechanically expanded PTFE is but one means of obtaining the desired porosity.
- Liquids having contact angles with PTFE less than 90° include non-polar organic solvents such as alkanes (pentane, hexane, heptane and octane, among others) and cycloalkanes, freons or related materials such as chlorofluorocarbons (“CFCs”) and hydrochlorofluorocarbons (“HCFCs”). Commercial solvents include CFCs and HCFCs such as “Techspray AMS Flux Remover” (from Techspray, Inc., of Amarillo, Tex.) and “Gensolv 2004” (from Micro Care Corp. of Bristol, Conn.). Various ethers, tetrahydrofuran, dioxane are among the solvents wetting PTFE. For some embodiments of the present invention, a candidate solvent is any solvent that is known to wet fluoropolymers (particularly ePTFE) or the hydrophobic polymer of interest. Although pure solvents are discussed herein, this is merely for economy of language. Mixtures of solvents that retain the property of being able to wet the hydrophobic surface, particularly ePTFE, are included within the scope of the present invention.
- Some invention embodiments specifically exclude solvent mixtures that comprise more than 10 weight percent, more than 20 weight percent, more than 30 weight percent, or more than 40 weight percent of a mixture of trifluoro trichloro ethanes.
- A hydrophobic complex of heparin is dissolved in the polymer-wetting primary solvent for penetration into the porous structure and deposition onto ePTFE in some embodiments of the present invention. Some (typically small) amount of heparin complex dissolves in pure polymer-wetting solvent as described above, but typically does not lead to biologically useful amounts of heparin being deposited onto the hydrophobic surfaces. Therefore, in some embodiments of the present invention, the solubility of heparin complexes is enhanced by the addition of relatively small amounts of a polar solvent to the non-polar primary solvent. The non-polar primary solvent is chosen to provide adequate penetration into the interior of the porous hydrophobic material, while the polar solubility-enhancing component of the solvent is selected to facilitate dissolution of heparin complexes in the solvent mixture. Candidate polar solubility-enhancing additives included organic alcohols (methanol, ethanol, among others), ketones (acetone, methylethylketone, among others). Mixtures of one or more chemical compounds can also be used as the solubility-enhancing solvent.
- In some embodiments, the solubility-enhancing component is limited to solvents or solvent mixtures that have at least the following two characteristics. First, the hemocompatible substance is more soluble in the solubility-enhancing component than the substance is in the polymer-wetting primary solvent. Second, the hemocompatible substance is more soluble in the solubility-enhancing component than it is in a mixture of the polymer-wetting primary solvent and the solubility-enhancing component. Such solubility-enhancing components are said to be particularly solubility enhancing.
- Some invention embodiments specifically exclude solvent mixtures that comprise more than 1 weight percent, more than 2 weight percent, more than 3 weight percent, more than 4 weight percent, more than 5 weight percent, more than 10 weight percent, more than 20 weight percent, more than 30 weight percent, or more than 40 weight percent of ethanol.
- It is desirable, but not inherently necessary in some embodiments of the present invention, that the polar solvent be added to the non-polar solvent in an amount so as to form an azeotropic mixture. Azeotropic mixtures have the property of evaporating such that the unevaporated liquid retains the same composition to dryness. In contrast, non-azeotropic mixtures typically become more concentrated in the less volatile solvent as evaporation proceeds. A solute will thus experience a changing solvent composition during evaporation for non-azeotropic mixtures. This may lead to precipitation of the solute and tend to create non-uniform coatings. Thus, while non-azeotropic mixtures may be used with acceptable results, azeotropic mixtures typically give better coatings.
- One example of a substantially azeotropic mixture described in detail below includes a polymer-wetting solvent HCFC-225 containing about 6% methanol (by volume). This solvent mixture is found to be adequate in the some embodiments of the present invention. “HCFC-225” is a mixture of isomers of dichloropentafluoropropane, typically HCFC-225ca is CF3CF2CHCl2 and HCFC225cb is CCIF2CF2CHFCl. However, azeotropic mixtures are not necessary in the present invention and adequate results are obtained with concentrations of polar solvent from approximately 0.00001% up to saturation of the polar solvent dissolved in the non-polar solvent. In some embodiments of the present invention, concentrations of polar solvent in the range from about 0.1% to about 10% by volume are used. However, while the above ranges give therapeutically useful amounts of hemocompatible substances, better quality coatings are typically obtained with concentrations in the range from approximately 0.1% to approximately 2%. A range from approximately 0.5% to approximately 1% is particularly useful in that 0.5% has enough hemocompatible material for therapeutically effective coatings by 1% is dilute enough to avoid webbing.
- Thus, the present invention includes adding relatively small amounts of an organic alcohol (such as ethanol, methanol, among others) or a similar solubility-enhancing polar solvent to a polymer-wetting solvent. The solubility enhancing solvent is added to the polymer-wetting solvent in such quantity (typically small) that the mixed solvent provides adequate solubility for heparin complexes without substantially hindering penetration of the pores or wetting of the hydrophobic polymer. Thus, in one embodiment a mixed solvent is created that both wets ePTFE and delivers heparin to all surfaces of the porous structure.
- Having dissolved a suitable heparin complex in a mixed solvent as described herein, coating of the ePTFE with the heparin complex may be performed by any convenient method that brings the heparin-containing solution into intimate contact with all surface regions of the ePTFE substrate including the interior regions of the pores. Dip coating is one technique that can be used in some embodiments of the present invention although other coating techniques known in the art may also be used, including spraying.
-
FIG. 3 depicts a portion of an endoluminal stent in cut-away view, showing the interior region of the stent, 1, the struts, 2, and a covering, 3. The covering material for the stent, 3, is typically porous to allow blood flowing on the interior of the stent, 1, to come into contact with the interior surfaces of the lumen in which the stent is placed. Porous materials containing hemocompatible substances thereon may be used in many medical devices, one example of which is stent covering, 3. Expanded PTFE is a typical stent covering material. Other materials for covering stents are described elsewhere herein and in the references cited. - Hemocompatible substances placed onto stent cover, 3, include heparin and heparin complexes. One embodiment of the present invention relates to coating a ePTFE stent covering material with a heparin complex, typically DURAFLO or DURAFLO II. Typical pore sizes of ePTFE are in the range of approximately 5 μm (microns) to approximately 200 μm, commonly in the range from approximately 40 μm to approximately 120 μm.
- DURAFLO II may be used herein in place of DURAFLO without modification.
-
- 1) Prepare a solution consisting of the hydrochlorofluorocarbon HCFC-225 and 6% by volume methanol whereby the methanol enhances the solubility of the heparin complex in the HCFC solvent.
- 2) Dissolve in the solution of step 1, a heparin complex, DURAFLO. The concentration of DURAFLO in the solution is selected to provide the desired coating of DURAFLO on the stent cover. Too little drug on the stent cover may be therapeutically ineffective. Too much may cause excess amounts of drug to be released into the blood soon after the stent is implanted, to the detriment of the patient.
- 3) Dip ePTFE into the solution of
step 2 allowing the solution to perfuse throughout the ePTFE porosity and deposit the DURAFLO throughout. - 4)
Repeat step 3 if additional coating of DURAFLO is desired.
Other solvents that may be used in step 1 above include the following: - 1-a) Techspray AMS Flux Remover containing approximately 6% methanol.
- 1-b) Genesolv 2004, dichlorofluoroethane containing approximately 4% methanol.
- 1-c) Cyclohexane including approximately 5% n-propanol.
Other solutes that may be used instep 2 above include the following: - 2-a) TDMEC heparin.
- 2-b) Benzalkonium heparin.
Concentrations of solute in solvent may be any convenient value leading to the appropriate deposition of hemocompatible substance onto the surface of the polymer. Typical concentrations in the range of approximately 1%-3% are found to give adequate coatings.
- The material produced by the above procedure is a suitable stent covering material containing DURAFLO (or other heparin complex) coated on substantially all surfaces thereof that will be exposed to blood during use. Dip or spray coating is conveniently done on a porous, hydrophobic polymer already mounted on the struts, forming thereby a stent covering. However, the hydrophobic, porous material may be coated pursuant to the present invention before, during or following the fabrication of the material into a medical device. The timing of coating and device fabrication is determined in part by manufacturing considerations including the damage likely to result to the hemocompatible substance by processing during device fabrication.
- The properties of the coating can be tested in vitro by standard testing methods including AT-III binding or anti-Factor Xa Assay. Other biological assays include various ex vivo shunts.
- This application hereby incorporated by reference the entire specification and claims of parent application, U.S. application Ser. No. 09/704,212.
- Having described the invention in detail, those skilled in the art will appreciate that, given the present disclosure, modifications may be made to the invention without departing from the spirit of the inventive concept described herein. Therefore, it is not intended that the scope of the invention be limited to the specific embodiments illustrated and described.
Claims (39)
1. A medical device, comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate produced by:
a) providing a hemocompatible substance,
b) preparing a solution comprising a mixture of:
first solvent that wets the porous hydrophobic polymer substrate;
a second solvent that enhances the solubility of the hemocompatible substance in the solution; and
the hemocompatible substance; and,
c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer substrate,
provided that the hemocompatible substance is not subjected to a dialdehyde cross-linking or dialdehyde stabilization step before in vivo use.
2. The medical device of claim 1 wherein the medical device is a stent.
3. The medical device of claim I wherein the porous hydrophobic polymer substrate composes a blood-contacting component of a medical device.
4. The medical device of claim I wherein the porous hydrophobic polymer substrate includes at least one polymer material selected from the group consisting of porous polyethylene materials, porous polypropylene materials, porous polyurethane materials, porous polyacrylate materials, porous polymethacrylate materials and porous fluoropolymer materials.
5. The medical device of claim 4 wherein the porous fluoropolymer material comprises an expanded poly(tetrafluoroethylene) material.
6. The medical device of claim 1 wherein the hemocompatible substance comprises ionic heparin and a hydrophobic counter ion.
7. The medical device of claim 6 wherein the hydrophobic counter ion is a hydrophobic quaternary ammonium ion.
9. The medical device of claim 6 wherein the hydrophobic counter ion is one or more of benzylalkonium ion and tridodecylmethylammonium ion.
10. The medical device of claim 1 wherein the hemocompatible substance is deposited on the hydrophobic polymer substrate by dipping.
11. The medical device of claim 10 wherein the second solvent particularly enhances solubility of the hemocompatible substance.
12. A medical device, comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate produced by:
a) providing a hemocompatible substance,
b) preparing a solution comprising a mixture of:
a first solvent that wets the porous hydrophobic polymer substrate;
a second solvent that particularly enhances the solubility of the hemocompatible substance in the solution; and
the hemocompatible substance; and
c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer.
13. The medical device of claim 12 wherein the medical device is a stent.
14. The medical device of claim 12 wherein the porous hydrophobic polymer substrate composes a blood-contacting component of a medical device.
16. The medical device of claim 12 wherein the porous hydrophobic polymer substrate includes at least one polymer material selected from the group consisting of porous polyethylene materials, porous polypropylene materials, porous polyurethane materials, porous polyacrylate materials, porous polymethacrylate materials and porous fluoropolymer materials.
17. The medical device of claim 16 wherein the porous fluoropolymer material comprises an expanded poly(tetrafluoroethylene) material.
18. The medical device of claim 12 wherein the hemocompatible substance comprises ionic heparin and a hydrophobic counter ion.
19. The medical device of claim 18 wherein the hydrophobic counter ion is a hydrophobic quaternary ammonium ion.
20. The medical device of claim 18 wherein the hydrophobic counter ion is one or more of benzylalkonium ion and tridodecylmethylammonium ion.
21. The medical device of claim 12 wherein the hemocompatible substance is deposited on the hydrophobic polymer substrate by dipping.
22. A medical device, comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate produced by:
a) providing a hemocompatible substance,
b) preparing a solution comprising a mixture of:
a first solvent that wets the porous hydrophobic polymer substrate;
a second solvent that enhances the solubility of the hemocompatible substance in the solution; and
the hemocompatible substance; and,
c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer substrate,
provided that the amount of a mixture of trichloro trifluoro ethanes is 10 wt % or less.
23. The medical device of claim 22 wherein the medical device is a stent.
24. The medical device of claim 22 wherein the porous hydrophobic polymer substrate composes a blood-contacting component of a medical device.
25. The medical device of claim 22 wherein the porous hydrophobic polymer substrate includes at least one polymer material selected from the group consisting of porous polyethylene materials, porous polypropylene materials, porous polyurethane materials, porous polyacrylate materials, porous polymethacrylate materials and porous fluoropolymer materials.
26. The medical device of claim 25 wherein the porous fluoropolymer material comprises an expanded poly(tetrafluoroethylene) material.
27. The medical device of claim 22 wherein the hemocompatible substance comprises ionic heparin and a hydrophobic counter ion.
28. The medical device of claim 27 wherein the hydrophobic counter ion is a hydrophobic quaternary ammonium ion.
29. The medical device of claim 27 wherein the hydrophobic counter ion is one or more of benzylalkonium ion and tridodecylmethylammonium ion.
30. The medical device of claim 22 wherein the hemocompatible substance is deposited on the hydrophobic polymer substrate by dipping.
31. The medical device of claim 30 wherein the second solvent particularly enhances solubility of the hemocompatible substance.
32. A medical device, comprising at least one blood-contacting surface comprising a porous hydrophobic polymer substrate, wherein at least a portion of the at least one blood-contacting surface comprises a hemocompatible polymer substrate produced by:
a) providing a hemocompatible substance,
b) preparing a solution comprising a mixture of:
a first solvent that wets the porous hydrophobic polymer substrate;
a second solvent that enhances the solubility of the hemocompatible substance in the solution; and
the hemocompatible substance; and
c) contacting the surface of the porous hydrophobic polymer substrate with the solution thereby causing the hemocompatible substance to deposit onto the surface of the porous hydrophobic polymer substrate,
provided that the solution has a maximum ethanol content of 10 wt %.
33. The medical device of claim 32 wherein the medical device is a stent.
34. The medical device of claim 32 wherein the porous hydrophobic polymer substrate composes a blood-contacting component of a medical device.
35. The medical device of claim 32 wherein the porous hydrophobic polymer substrate includes at least one polymer material selected from the group consisting of porous polyethylene materials, porous polypropylene materials, porous polyurethane materials, porous polyacrylate materials, porous polymethacrylate materials and porous fluoropolymer materials.
36. The medical device of claim 35 wherein the porous fluoropolymer material comprises an expanded poly(tetrafluoroethylene) material.
37. The medical device of claim 32 wherein the hemocompatible substance comprises ionic heparin and a hydrophobic counter ion.
38. The medical device of claim 37 wherein the hydrophobic counter ion is a hydrophobic quaternary ammonium ion.
39. The medical device of claim 37 wherein the hydrophobic counter ion is one or more of benzylalkonium ion and tridodecylmethylammonium ion.
40. The medical device of claim 32 wherein the hemocompatible substance is deposited on the hydrophobic polymer substrate by dipping.
41. The medical device of claim 40 wherein the second solvent particularly enhances solubility of the hemocompatible substance.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/021,195 US20080125857A1 (en) | 2000-10-31 | 2008-01-28 | Hemocompatible polymers on hydrophobic porous polymers |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/704,212 US6833153B1 (en) | 2000-10-31 | 2000-10-31 | Hemocompatible coatings on hydrophobic porous polymers |
US10/818,927 US7807210B1 (en) | 2000-10-31 | 2004-04-05 | Hemocompatible polymers on hydrophobic porous polymers |
US12/021,195 US20080125857A1 (en) | 2000-10-31 | 2008-01-28 | Hemocompatible polymers on hydrophobic porous polymers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/818,927 Division US7807210B1 (en) | 2000-10-31 | 2004-04-05 | Hemocompatible polymers on hydrophobic porous polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080125857A1 true US20080125857A1 (en) | 2008-05-29 |
Family
ID=39476595
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/818,927 Expired - Fee Related US7807210B1 (en) | 2000-10-31 | 2004-04-05 | Hemocompatible polymers on hydrophobic porous polymers |
US12/021,199 Abandoned US20080132592A1 (en) | 2000-10-31 | 2008-01-28 | Hemocompatible polymers on hydrophobic porous polymers |
US12/021,195 Abandoned US20080125857A1 (en) | 2000-10-31 | 2008-01-28 | Hemocompatible polymers on hydrophobic porous polymers |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/818,927 Expired - Fee Related US7807210B1 (en) | 2000-10-31 | 2004-04-05 | Hemocompatible polymers on hydrophobic porous polymers |
US12/021,199 Abandoned US20080132592A1 (en) | 2000-10-31 | 2008-01-28 | Hemocompatible polymers on hydrophobic porous polymers |
Country Status (1)
Country | Link |
---|---|
US (3) | US7807210B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011089624A2 (en) | 2010-01-22 | 2011-07-28 | Concept Medical Research Private Limited | Insertable medical devices with a porous bed for delivering nano-carriers to a target site and methods of preparing the same |
EP2450068A1 (en) * | 2009-01-15 | 2012-05-09 | Sungkyunkwan University Foundation For Corporate Collaboration | Bioactive material coating method and tube |
WO2017049308A1 (en) * | 2015-09-17 | 2017-03-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Biostable segmented elastomers and thermoplastics and methods of making and using thereof |
WO2022113019A1 (en) * | 2020-11-27 | 2022-06-02 | Uniwersytet Śląski W Katowicach | A membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and the method of obtaining it |
WO2022113015A1 (en) * | 2020-11-27 | 2022-06-02 | Uniwersytet Śląski W Katowicach | Organic material with pore-forming, anti-inflammatory and anticoagulant properties and the method of its preparation |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008098087A2 (en) * | 2007-02-06 | 2008-08-14 | Glumetrics, Inc. | Optical systems and methods for rationmetric measurement of blood glucose concentration |
JP5517919B2 (en) * | 2007-05-10 | 2014-06-11 | グルメトリクス、 インク. | Balanced non-consumable fluorescent sensor for immediate intravascular glucose measurement |
JP5631215B2 (en) | 2007-11-21 | 2014-11-26 | メドトロニック ミニメド インコーポレイテッド | Blood sugar management maintenance system |
US20110077477A1 (en) * | 2009-09-30 | 2011-03-31 | Glumetrics, Inc. | Sensors with thromboresistant coating |
US9381112B1 (en) | 2011-10-06 | 2016-07-05 | William Eric Sponsell | Bleb drainage device, ophthalmological product and methods |
US8632489B1 (en) | 2011-12-22 | 2014-01-21 | A. Mateen Ahmed | Implantable medical assembly and methods |
Citations (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2072303A (en) * | 1932-10-18 | 1937-03-02 | Chemische Forschungs Gmbh | Artificial threads, bands, tubes, and the like for surgical and other purposes |
US3953566A (en) * | 1970-05-21 | 1976-04-27 | W. L. Gore & Associates, Inc. | Process for producing porous products |
US4654327A (en) * | 1982-04-21 | 1987-03-31 | Research Corp. | Quaternary ammonium complexes of heparin |
US4656242A (en) * | 1985-06-07 | 1987-04-07 | Henkel Corporation | Poly(ester-amide) compositions |
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) * | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4895566A (en) * | 1986-07-25 | 1990-01-23 | C. R. Bard, Inc. | Coating medical devices with cationic antibiotics |
US5100992A (en) * | 1989-05-04 | 1992-03-31 | Biomedical Polymers International, Ltd. | Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
US5181903A (en) * | 1988-03-25 | 1993-01-26 | Duke University | Method for improving a biomaterial's resistance to thrombosis and infection and for improving tissue ingrowth |
US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
US5298260A (en) * | 1990-05-01 | 1994-03-29 | Mediventures, Inc. | Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality |
US5300295A (en) * | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
US5306501A (en) * | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
US5306786A (en) * | 1990-12-21 | 1994-04-26 | U C B S.A. | Carboxyl group-terminated polyesteramides |
US5380299A (en) * | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
US5383927A (en) * | 1992-05-07 | 1995-01-24 | Intervascular Inc. | Non-thromogenic vascular prosthesis |
US5485496A (en) * | 1994-09-22 | 1996-01-16 | Cornell Research Foundation, Inc. | Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties |
US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5607467A (en) * | 1990-09-14 | 1997-03-04 | Froix; Michael | Expandable polymeric stent with memory and delivery apparatus and method |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5610241A (en) * | 1996-05-07 | 1997-03-11 | Cornell Research Foundation, Inc. | Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers |
US5616338A (en) * | 1988-02-11 | 1997-04-01 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
US5624411A (en) * | 1993-04-26 | 1997-04-29 | Medtronic, Inc. | Intravascular stent and method |
US5711958A (en) * | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US5721131A (en) * | 1987-03-06 | 1998-02-24 | United States Of America As Represented By The Secretary Of The Navy | Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells |
US5723219A (en) * | 1995-12-19 | 1998-03-03 | Talison Research | Plasma deposited film networks |
US5735897A (en) * | 1993-10-19 | 1998-04-07 | Scimed Life Systems, Inc. | Intravascular stent pump |
US5858746A (en) * | 1992-04-20 | 1999-01-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5865814A (en) * | 1995-06-07 | 1999-02-02 | Medtronic, Inc. | Blood contacting medical device and method |
US5869127A (en) * | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US5873904A (en) * | 1995-06-07 | 1999-02-23 | Cook Incorporated | Silver implantable medical device |
US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US5876433A (en) * | 1996-05-29 | 1999-03-02 | Ethicon, Inc. | Stent and method of varying amounts of heparin coated thereon to control treatment |
US5879713A (en) * | 1994-10-12 | 1999-03-09 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US5879697A (en) * | 1997-04-30 | 1999-03-09 | Schneider Usa Inc | Drug-releasing coatings for medical devices |
US6011125A (en) * | 1998-09-25 | 2000-01-04 | General Electric Company | Amide modified polyesters |
US6010530A (en) * | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
US6015541A (en) * | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US6033582A (en) * | 1996-01-22 | 2000-03-07 | Etex Corporation | Surface modification of medical implants |
US6034204A (en) * | 1997-08-08 | 2000-03-07 | Basf Aktiengesellschaft | Condensation products of basic amino acids with copolymerizable compounds and a process for their production |
US6048484A (en) * | 1993-08-18 | 2000-04-11 | W. L. Gore & Associates, Inc. | Process for forming a seamless tube of expanded PTFE from a sheet of expanded PTFE |
US6051648A (en) * | 1995-12-18 | 2000-04-18 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
US6172167B1 (en) * | 1996-06-28 | 2001-01-09 | Universiteit Twente | Copoly(ester-amides) and copoly(ester-urethanes) |
US6177523B1 (en) * | 1999-07-14 | 2001-01-23 | Cardiotech International, Inc. | Functionalized polyurethanes |
US6180632B1 (en) * | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6203551B1 (en) * | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6335029B1 (en) * | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US6338904B1 (en) * | 1996-11-25 | 2002-01-15 | Scimed Life Systems | Polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents |
US20020007215A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007213A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007214A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020005206A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US20020009604A1 (en) * | 1999-12-22 | 2002-01-24 | Zamora Paul O. | Plasma-deposited coatings, devices and methods |
US6344035B1 (en) * | 1998-04-27 | 2002-02-05 | Surmodics, Inc. | Bioactive agent release coating |
US20020016625A1 (en) * | 2000-05-12 | 2002-02-07 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020032414A1 (en) * | 1998-08-20 | 2002-03-14 | Ragheb Anthony O. | Coated implantable medical device |
US6358556B1 (en) * | 1995-04-19 | 2002-03-19 | Boston Scientific Corporation | Drug release stent coating |
US20030004141A1 (en) * | 2001-03-08 | 2003-01-02 | Brown David L. | Medical devices, compositions and methods for treating vulnerable plaque |
US6503556B2 (en) * | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US6503538B1 (en) * | 2000-08-30 | 2003-01-07 | Cornell Research Foundation, Inc. | Elastomeric functional biodegradable copolyester amides and copolyester urethanes |
US6503954B1 (en) * | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
US6506437B1 (en) * | 2000-10-17 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device having depots formed in a surface thereof |
US20030028243A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US20030028244A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US20030032767A1 (en) * | 2001-02-05 | 2003-02-13 | Yasuhiro Tada | High-strength polyester-amide fiber and process for producing the same |
US20030036794A1 (en) * | 1995-06-07 | 2003-02-20 | Cook Incorporated | Coated implantable medical device |
US6524347B1 (en) * | 1997-05-28 | 2003-02-25 | Avantis Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20030040712A1 (en) * | 1999-07-13 | 2003-02-27 | Pinaki Ray | Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway |
US20030039689A1 (en) * | 2001-04-26 | 2003-02-27 | Jianbing Chen | Polymer-based, sustained release drug delivery system |
US6527863B1 (en) * | 2001-06-29 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Support device for a stent and a method of using the same to coat a stent |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US20030059520A1 (en) * | 2001-09-27 | 2003-03-27 | Yung-Ming Chen | Apparatus for regulating temperature of a composition and a method of coating implantable devices |
US20030060877A1 (en) * | 2001-09-25 | 2003-03-27 | Robert Falotico | Coated medical devices for the treatment of vascular disease |
US6673385B1 (en) * | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US6673154B1 (en) * | 2001-06-28 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Stent mounting device to coat a stent |
US20040018296A1 (en) * | 2000-05-31 | 2004-01-29 | Daniel Castro | Method for depositing a coating onto a surface of a prosthesis |
US6689099B2 (en) * | 1999-07-13 | 2004-02-10 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
US20040029952A1 (en) * | 1999-09-03 | 2004-02-12 | Yung-Ming Chen | Ethylene vinyl alcohol composition and coating |
US6695920B1 (en) * | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US20040047978A1 (en) * | 2000-08-04 | 2004-03-11 | Hossainy Syed F.A. | Composition for coating an implantable prosthesis |
US20040047980A1 (en) * | 2000-12-28 | 2004-03-11 | Pacetti Stephen D. | Method of forming a diffusion barrier layer for implantable devices |
US6706013B1 (en) * | 2001-06-29 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Variable length drug delivery catheter |
US20040054104A1 (en) * | 2002-09-05 | 2004-03-18 | Pacetti Stephen D. | Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol) |
US20040052858A1 (en) * | 2001-05-09 | 2004-03-18 | Wu Steven Z. | Microparticle coated medical device |
US6709514B1 (en) * | 2001-12-28 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Rotary coating apparatus for coating implantable medical devices |
US6712845B2 (en) * | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US6713119B2 (en) * | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
Family Cites Families (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2386454A (en) | 1940-11-22 | 1945-10-09 | Bell Telephone Labor Inc | High molecular weight linear polyester-amides |
US3849514A (en) | 1967-11-17 | 1974-11-19 | Eastman Kodak Co | Block polyester-polyamide copolymers |
US3773737A (en) | 1971-06-09 | 1973-11-20 | Sutures Inc | Hydrolyzable polymers of amino acid and hydroxy acids |
SE400173B (en) * | 1975-03-20 | 1978-03-20 | Aminkemi Ab | PROCEDURE FOR STABILIZING A HEPARINIZED SURFACE CONTAINING FOR BLOOD CONTACT RELEASE HEPARIN |
US4045365A (en) * | 1976-05-13 | 1977-08-30 | Allied Chemical Corporation | Azeotrope-like compositions of trichloro-trifluoroethane, acetonitrile and acetone |
CA1147087A (en) | 1977-12-21 | 1983-05-24 | David Goldfarb | Graphite impregnated prosthetic vascular graft materials |
US4329383A (en) | 1979-07-24 | 1982-05-11 | Nippon Zeon Co., Ltd. | Non-thrombogenic material comprising substrate which has been reacted with heparin |
SU790725A1 (en) | 1979-07-27 | 1983-01-23 | Ордена Ленина Институт Элементоорганических Соединений Ан Ссср | Process for preparing alkylaromatic polyimides |
US4226243A (en) | 1979-07-27 | 1980-10-07 | Ethicon, Inc. | Surgical devices of polyesteramides derived from bis-oxamidodiols and dicarboxylic acids |
SU811750A1 (en) | 1979-08-07 | 1983-09-23 | Институт Физиологии Им.С.И.Бериташвили | Bis-bicarbonates of aliphatic diols as monomers for preparing polyurethanes and process for producing the same |
SU872531A1 (en) | 1979-08-07 | 1981-10-15 | Институт Физиологии Им.И.С.Бериташвили Ан Гсср | Method of producing polyurethans |
SU876663A1 (en) | 1979-11-11 | 1981-10-30 | Институт Физиологии Им. Академика И.С.Бериташвили Ан Гсср | Method of producing polyarylates |
US4343931A (en) | 1979-12-17 | 1982-08-10 | Minnesota Mining And Manufacturing Company | Synthetic absorbable surgical devices of poly(esteramides) |
SU1016314A1 (en) | 1979-12-17 | 1983-05-07 | Институт Физиологии Им.И.С.Бериташвили | Process for producing polyester urethanes |
US4529792A (en) | 1979-12-17 | 1985-07-16 | Minnesota Mining And Manufacturing Company | Process for preparing synthetic absorbable poly(esteramides) |
SU905228A1 (en) | 1980-03-06 | 1982-02-15 | Институт Физиологии Им. Акад.И.С. Бериташвили Ан Гсср | Method for preparing thiourea |
US4531916A (en) | 1983-07-08 | 1985-07-30 | W. L. Gore & Associates, Inc. | Dental implant with expanded PTFE gingival interface |
JPS6145765A (en) | 1984-08-07 | 1986-03-05 | 宇部興産株式会社 | Blood vessel prosthesis and its production |
SU1293518A1 (en) | 1985-04-11 | 1987-02-28 | Тбилисский зональный научно-исследовательский и проектный институт типового и экспериментального проектирования жилых и общественных зданий | Installation for testing specimen of cross-shaped structure |
US4611051A (en) | 1985-12-31 | 1986-09-09 | Union Camp Corporation | Novel poly(ester-amide) hot-melt adhesives |
US4871357A (en) * | 1986-01-21 | 1989-10-03 | Baxter International Inc. | Ionic heparin coating |
US4745105A (en) | 1986-08-20 | 1988-05-17 | Griffin Charles C | Low molecular weight heparin derivatives with improved permeability |
US4745107A (en) | 1986-08-20 | 1988-05-17 | Foley Kevin M | Heparin derivatives with improved permeability |
US4882168A (en) | 1986-09-05 | 1989-11-21 | American Cyanamid Company | Polyesters containing alkylene oxide blocks as drug delivery systems |
JPH0696023B2 (en) | 1986-11-10 | 1994-11-30 | 宇部日東化成株式会社 | Artificial blood vessel and method for producing the same |
US5073265A (en) * | 1987-02-27 | 1991-12-17 | Johnson Richard J | Methods of manufacturing nucleophilic material modified for improved biocompatibility |
US6387379B1 (en) | 1987-04-10 | 2002-05-14 | University Of Florida | Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like |
US4894231A (en) | 1987-07-28 | 1990-01-16 | Biomeasure, Inc. | Therapeutic agent delivery system |
US5047020A (en) | 1987-09-14 | 1991-09-10 | Baxter International Inc. | Ionic heparin coating |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
JP2561309B2 (en) | 1988-03-28 | 1996-12-04 | テルモ株式会社 | Medical material and manufacturing method thereof |
US5013717A (en) | 1988-04-18 | 1991-05-07 | Becton, Dickinson And Company | Blood compatible, lubricious article and composition and method therefor |
US5061738A (en) | 1988-04-18 | 1991-10-29 | Becton, Dickinson And Company | Blood compatible, lubricious article and composition and method therefor |
US4931287A (en) | 1988-06-14 | 1990-06-05 | University Of Utah | Heterogeneous interpenetrating polymer networks for the controlled release of drugs |
US5328471A (en) | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
US4977901A (en) | 1988-11-23 | 1990-12-18 | Minnesota Mining And Manufacturing Company | Article having non-crosslinked crystallized polymer coatings |
US5272012A (en) | 1989-06-23 | 1993-12-21 | C. R. Bard, Inc. | Medical apparatus having protective, lubricious coating |
US5069899A (en) | 1989-11-02 | 1991-12-03 | Sterilization Technical Services, Inc. | Anti-thrombogenic, anti-microbial compositions containing heparin |
US5525348A (en) | 1989-11-02 | 1996-06-11 | Sts Biopolymers, Inc. | Coating compositions comprising pharmaceutical agents |
JPH03173838A (en) * | 1989-12-01 | 1991-07-29 | Asahi Glass Co Ltd | Fluorinated hydrocarbon-based azeotropic composition |
US5135516A (en) | 1989-12-15 | 1992-08-04 | Boston Scientific Corporation | Lubricious antithrombogenic catheters, guidewires and coatings |
US5971954A (en) | 1990-01-10 | 1999-10-26 | Rochester Medical Corporation | Method of making catheter |
EP0514406B1 (en) | 1990-01-30 | 1994-03-02 | Akzo Nobel N.V. | Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances |
WO1991017724A1 (en) | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Medical device polymer |
US6060451A (en) | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
CA2038605C (en) | 1990-06-15 | 2000-06-27 | Leonard Pinchuk | Crack-resistant polycarbonate urethane polymer prostheses and the like |
ATE123658T1 (en) | 1990-06-15 | 1995-06-15 | Cortrak Medical Inc | DEVICE FOR DISPENSING MEDICATIONS. |
US5112457A (en) | 1990-07-23 | 1992-05-12 | Case Western Reserve University | Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants |
US5455040A (en) | 1990-07-26 | 1995-10-03 | Case Western Reserve University | Anticoagulant plasma polymer-modified substrate |
US6248129B1 (en) | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
US5163952A (en) | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5322659A (en) | 1990-09-21 | 1994-06-21 | Becton, Dickinson And Company | Method for rendering a substrate surface antithrombogenic and/or anti-infective |
US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
DE69201193T2 (en) | 1991-05-31 | 1995-09-07 | Baxter International Inc., Deerfield, Ill. | FOAM-PRESSURE COAGLING RESISTANT COATING. |
US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
WO1993005825A1 (en) | 1991-09-20 | 1993-04-01 | Baxter International Inc. | Processes for reducing the thrombogenicity of biomaterials |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
GB9206736D0 (en) | 1992-03-27 | 1992-05-13 | Sandoz Ltd | Improvements of organic compounds and their use in pharmaceutical compositions |
US5219980A (en) | 1992-04-16 | 1993-06-15 | Sri International | Polymers biodegradable or bioerodiable into amino acids |
US5417981A (en) | 1992-04-28 | 1995-05-23 | Terumo Kabushiki Kaisha | Thermoplastic polymer composition and medical devices made of the same |
DE4224401A1 (en) | 1992-07-21 | 1994-01-27 | Pharmatech Gmbh | New biodegradable homo- and co-polymer(s) for pharmaceutical use - produced by polycondensation of prod. from heterolytic cleavage of aliphatic polyester with functionalised (cyclo)aliphatic cpd. |
US5441759A (en) | 1992-09-03 | 1995-08-15 | Sherwood Medical Company | Method to stabilize TDMAC heparin coating |
EP0623150A4 (en) | 1992-11-19 | 1999-08-25 | Univ Case Western Reserve | Nonthrombogenic implant surfaces. |
FR2699168B1 (en) | 1992-12-11 | 1995-01-13 | Rhone Poulenc Chimie | Method of treating a material comprising a polymer by hydrolysis. |
EP0604022A1 (en) | 1992-12-22 | 1994-06-29 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method for its manufacture |
US20020055710A1 (en) | 1998-04-30 | 2002-05-09 | Ronald J. Tuch | Medical device for delivering a therapeutic agent and method of preparation |
US5824048A (en) | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
JPH0767895A (en) | 1993-06-25 | 1995-03-14 | Sumitomo Electric Ind Ltd | Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation |
EG20321A (en) | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
DE4327024A1 (en) | 1993-08-12 | 1995-02-16 | Bayer Ag | Thermoplastically processable and biodegradable aliphatic polyesteramides |
JPH09501583A (en) | 1993-08-18 | 1997-02-18 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | Tubular endoluminal implant |
US5723004A (en) | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
AU1684595A (en) | 1994-01-21 | 1995-08-08 | Brown University Research Foundation | Biocompatible implants |
CA2190121A1 (en) | 1994-03-15 | 1995-09-21 | Edith Mathiowitz | Polymeric gene delivery system |
US5567410A (en) | 1994-06-24 | 1996-10-22 | The General Hospital Corporation | Composotions and methods for radiographic imaging |
US5670558A (en) | 1994-07-07 | 1997-09-23 | Terumo Kabushiki Kaisha | Medical instruments that exhibit surface lubricity when wetted |
US5788979A (en) | 1994-07-22 | 1998-08-04 | Inflow Dynamics Inc. | Biodegradable coating with inhibitory properties for application to biocompatible materials |
US5516881A (en) | 1994-08-10 | 1996-05-14 | Cornell Research Foundation, Inc. | Aminoxyl-containing radical spin labeling in polymers and copolymers |
US5578073A (en) | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
US5649977A (en) | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
FR2724938A1 (en) | 1994-09-28 | 1996-03-29 | Lvmh Rech | POLYMERS FUNCTIONALIZED BY AMINO ACIDS OR AMINO ACID DERIVATIVES, THEIR USE AS SURFACTANTS, IN PARTICULAR, IN COSMETIC COMPOSITIONS AND IN PARTICULAR NAIL POLISH. |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5569198A (en) | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
US6017577A (en) | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
WO1996025897A2 (en) | 1995-02-22 | 1996-08-29 | Menlo Care, Inc. | Covered expanding mesh stent |
US5702754A (en) | 1995-02-22 | 1997-12-30 | Meadox Medicals, Inc. | Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US5854376A (en) | 1995-03-09 | 1998-12-29 | Sekisui Kaseihin Kogyo Kabushiki Kaisha | Aliphatic ester-amide copolymer resins |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
NZ305471A (en) | 1995-04-19 | 2000-02-28 | Kazunori Kataoka | Use of heterotelechelic block copolymers as carriers for medicaments |
US20020091433A1 (en) | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US5674242A (en) | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US5667767A (en) | 1995-07-27 | 1997-09-16 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels |
US5658995A (en) | 1995-11-27 | 1997-08-19 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
DE19545678A1 (en) | 1995-12-07 | 1997-06-12 | Goldschmidt Ag Th | Copolymers of polyamino acid esters |
US6054553A (en) | 1996-01-29 | 2000-04-25 | Bayer Ag | Process for the preparation of polymers having recurring agents |
US5932299A (en) | 1996-04-23 | 1999-08-03 | Katoot; Mohammad W. | Method for modifying the surface of an object |
US5955509A (en) | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
US5914182A (en) * | 1996-06-03 | 1999-06-22 | Gore Hybrid Technologies, Inc. | Materials and methods for the immobilization of bioactive species onto polymeric substrates |
US5874165A (en) | 1996-06-03 | 1999-02-23 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto polymeric subtrates |
US5830178A (en) | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
US6060518A (en) | 1996-08-16 | 2000-05-09 | Supratek Pharma Inc. | Polymer compositions for chemotherapy and methods of treatment using the same |
US5783657A (en) | 1996-10-18 | 1998-07-21 | Union Camp Corporation | Ester-terminated polyamides of polymerized fatty acids useful in formulating transparent gels in low polarity liquids |
US6120491A (en) | 1997-11-07 | 2000-09-19 | The State University Rutgers | Biodegradable, anionic polymers derived from the amino acid L-tyrosine |
US5980972A (en) | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5997517A (en) | 1997-01-27 | 1999-12-07 | Sts Biopolymers, Inc. | Bonding layers for medical device surface coatings |
CA2278613A1 (en) | 1997-01-28 | 1998-07-30 | United States Surgical Corporation | Polyesteramide, its preparation and surgical devices fabricated therefrom |
ES2229475T3 (en) | 1997-01-28 | 2005-04-16 | United States Surgical Corporation | MOLDED SURGICAL DEVICE MANUFACTURED FROM POLYESTERAMIDS WITH GROUPS DERIVED FROM AMINO ACIDS WHICH ALTERNATE WITH GROUPS DERIVED FROM ALFA-HYDROXIACIDES. |
AU6254498A (en) | 1997-01-28 | 1998-08-18 | United States Surgical Corporation | Polyesteramide, its preparation and surgical devices fabricated therefrom |
US6240616B1 (en) | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6056993A (en) | 1997-05-30 | 2000-05-02 | Schneider (Usa) Inc. | Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel |
JPH1115184A (en) * | 1997-06-23 | 1999-01-22 | Sharp Corp | Electrophotographic photoreceptor and its production |
US6110483A (en) | 1997-06-23 | 2000-08-29 | Sts Biopolymers, Inc. | Adherent, flexible hydrogel and medicated coatings |
US6211249B1 (en) | 1997-07-11 | 2001-04-03 | Life Medical Sciences, Inc. | Polyester polyether block copolymers |
US5980928A (en) | 1997-07-29 | 1999-11-09 | Terry; Paul B. | Implant for preventing conjunctivitis in cattle |
US6121027A (en) | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
US6120788A (en) | 1997-10-16 | 2000-09-19 | Bioamide, Inc. | Bioabsorbable triglycolic acid poly(ester-amide)s |
US5955588A (en) | 1997-12-22 | 1999-09-21 | Innerdyne, Inc. | Non-thrombogenic coating composition and methods for using same |
US6110188A (en) | 1998-03-09 | 2000-08-29 | Corvascular, Inc. | Anastomosis method |
US6258371B1 (en) | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
US7658727B1 (en) | 1998-04-20 | 2010-02-09 | Medtronic, Inc | Implantable medical device with enhanced biocompatibility and biostability |
US20020188037A1 (en) | 1999-04-15 | 2002-12-12 | Chudzik Stephen J. | Method and system for providing bioactive agent release coating |
US6113629A (en) | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
KR100314496B1 (en) | 1998-05-28 | 2001-11-22 | 윤동진 | Non-thrombogenic heparin derivatives, process for preparation and use thereof |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
US6096027A (en) | 1998-09-30 | 2000-08-01 | Impra, Inc., A Subsidiary Of C.R. Bard, Inc. | Bag enclosed stent loading apparatus |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6143354A (en) | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
US6090134A (en) | 1999-02-16 | 2000-07-18 | Polymerex Medical Corp. | Surface fluorinated stent and methods thereof |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6287628B1 (en) | 1999-09-03 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6749626B1 (en) | 2000-03-31 | 2004-06-15 | Advanced Cardiovascular Systems, Inc. | Actinomycin D for the treatment of vascular disease |
US6379381B1 (en) | 1999-09-03 | 2002-04-30 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6759054B2 (en) | 1999-09-03 | 2004-07-06 | Advanced Cardiovascular Systems, Inc. | Ethylene vinyl alcohol composition and coating |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
US6241710B1 (en) * | 1999-12-20 | 2001-06-05 | Tricardia Llc | Hypodermic needle with weeping tip and method of use |
US6908624B2 (en) | 1999-12-23 | 2005-06-21 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
AU2599501A (en) | 1999-12-29 | 2001-07-09 | Advanced Cardiovascular Systems Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
US6255027B1 (en) * | 2000-05-22 | 2001-07-03 | Xerox Corporation | Blocking layer with light scattering particles having coated core |
US6585765B1 (en) | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
US20020077693A1 (en) | 2000-12-19 | 2002-06-20 | Barclay Bruce J. | Covered, coiled drug delivery stent and method |
US6417153B1 (en) * | 2000-07-20 | 2002-07-09 | 3M Innovative Properties Company | Azeotrope-like compositions and their use |
US6555157B1 (en) | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
AU2001278055A1 (en) | 2000-07-27 | 2002-02-13 | Rutgers, The State University | Therapeutic polyesters and polyamides |
US6585926B1 (en) | 2000-08-31 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a porous balloon |
US6254632B1 (en) | 2000-09-28 | 2001-07-03 | Advanced Cardiovascular Systems, Inc. | Implantable medical device having protruding surface structures for drug delivery and cover attachment |
US6716444B1 (en) | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US20020111590A1 (en) | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
US6746773B2 (en) | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US20020051730A1 (en) | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
US6558733B1 (en) | 2000-10-26 | 2003-05-06 | Advanced Cardiovascular Systems, Inc. | Method for etching a micropatterned microdepot prosthesis |
US6758859B1 (en) | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
US20020082679A1 (en) | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US6824559B2 (en) | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
US6544543B1 (en) | 2000-12-27 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Periodic constriction of vessels to treat ischemic tissue |
US6540776B2 (en) | 2000-12-28 | 2003-04-01 | Advanced Cardiovascular Systems, Inc. | Sheath for a prosthesis and methods of forming the same |
US20020087123A1 (en) | 2001-01-02 | 2002-07-04 | Hossainy Syed F.A. | Adhesion of heparin-containing coatings to blood-contacting surfaces of medical devices |
US6645195B1 (en) | 2001-01-05 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intraventricularly guided agent delivery system and method of use |
US6544223B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon catheter for delivering therapeutic agents |
US6544582B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for coating an implantable device |
US6740040B1 (en) | 2001-01-30 | 2004-05-25 | Advanced Cardiovascular Systems, Inc. | Ultrasound energy driven intraventricular catheter to treat ischemia |
WO2002064014A2 (en) | 2001-02-09 | 2002-08-22 | Endoluminal Therapeutics, Inc. | Endomural therapy |
US6780424B2 (en) | 2001-03-30 | 2004-08-24 | Charles David Claude | Controlled morphologies in polymer drug for release of drugs from polymer films |
US6623448B2 (en) | 2001-03-30 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Steerable drug delivery device |
US6645135B1 (en) | 2001-03-30 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intravascular catheter device and method for simultaneous local delivery of radiation and a therapeutic substance |
US6625486B2 (en) | 2001-04-11 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for intracellular delivery of an agent |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US6660034B1 (en) | 2001-04-30 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Stent for increasing blood flow to ischemic tissues and a method of using the same |
US7651695B2 (en) | 2001-05-18 | 2010-01-26 | Advanced Cardiovascular Systems, Inc. | Medicated stents for the treatment of vascular disease |
US6743462B1 (en) | 2001-05-31 | 2004-06-01 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for coating implantable devices |
US7862495B2 (en) | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
US6605154B1 (en) | 2001-05-31 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stent mounting device |
US6666880B1 (en) | 2001-06-19 | 2003-12-23 | Advised Cardiovascular Systems, Inc. | Method and system for securing a coated stent to a balloon catheter |
US6572644B1 (en) | 2001-06-27 | 2003-06-03 | Advanced Cardiovascular Systems, Inc. | Stent mounting device and a method of using the same to coat a stent |
US6565659B1 (en) | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
US6585755B2 (en) | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US6656216B1 (en) | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
EP1273314A1 (en) | 2001-07-06 | 2003-01-08 | Terumo Kabushiki Kaisha | Stent |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
WO2003028590A1 (en) | 2001-09-24 | 2003-04-10 | Medtronic Ave Inc. | Rational drug therapy device and methods |
US6753071B1 (en) | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US20030073961A1 (en) | 2001-09-28 | 2003-04-17 | Happ Dorrie M. | Medical device containing light-protected therapeutic agent and a method for fabricating thereof |
US20030065377A1 (en) | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US7585516B2 (en) | 2001-11-12 | 2009-09-08 | Advanced Cardiovascular Systems, Inc. | Coatings for drug delivery devices |
US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
US20040063805A1 (en) | 2002-09-19 | 2004-04-01 | Pacetti Stephen D. | Coatings for implantable medical devices and methods for fabrication thereof |
US7087263B2 (en) | 2002-10-09 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Rare limiting barriers for implantable medical devices |
-
2004
- 2004-04-05 US US10/818,927 patent/US7807210B1/en not_active Expired - Fee Related
-
2008
- 2008-01-28 US US12/021,199 patent/US20080132592A1/en not_active Abandoned
- 2008-01-28 US US12/021,195 patent/US20080125857A1/en not_active Abandoned
Patent Citations (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2072303A (en) * | 1932-10-18 | 1937-03-02 | Chemische Forschungs Gmbh | Artificial threads, bands, tubes, and the like for surgical and other purposes |
US3953566A (en) * | 1970-05-21 | 1976-04-27 | W. L. Gore & Associates, Inc. | Process for producing porous products |
US4187390A (en) * | 1970-05-21 | 1980-02-05 | W. L. Gore & Associates, Inc. | Porous products and process therefor |
US4654327A (en) * | 1982-04-21 | 1987-03-31 | Research Corp. | Quaternary ammonium complexes of heparin |
US4656242A (en) * | 1985-06-07 | 1987-04-07 | Henkel Corporation | Poly(ester-amide) compositions |
US4733665B1 (en) * | 1985-11-07 | 1994-01-11 | Expandable Grafts Partnership | Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4895566A (en) * | 1986-07-25 | 1990-01-23 | C. R. Bard, Inc. | Coating medical devices with cationic antibiotics |
US5721131A (en) * | 1987-03-06 | 1998-02-24 | United States Of America As Represented By The Secretary Of The Navy | Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells |
US4800882A (en) * | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US5616338A (en) * | 1988-02-11 | 1997-04-01 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
US5181903A (en) * | 1988-03-25 | 1993-01-26 | Duke University | Method for improving a biomaterial's resistance to thrombosis and infection and for improving tissue ingrowth |
US5100992A (en) * | 1989-05-04 | 1992-03-31 | Biomedical Polymers International, Ltd. | Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
US5298260A (en) * | 1990-05-01 | 1994-03-29 | Mediventures, Inc. | Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality |
US5300295A (en) * | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
US5306501A (en) * | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
US5607467A (en) * | 1990-09-14 | 1997-03-04 | Froix; Michael | Expandable polymeric stent with memory and delivery apparatus and method |
US5306786A (en) * | 1990-12-21 | 1994-04-26 | U C B S.A. | Carboxyl group-terminated polyesteramides |
US5858746A (en) * | 1992-04-20 | 1999-01-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5383927A (en) * | 1992-05-07 | 1995-01-24 | Intervascular Inc. | Non-thromogenic vascular prosthesis |
US5624411A (en) * | 1993-04-26 | 1997-04-29 | Medtronic, Inc. | Intravascular stent and method |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6048484A (en) * | 1993-08-18 | 2000-04-11 | W. L. Gore & Associates, Inc. | Process for forming a seamless tube of expanded PTFE from a sheet of expanded PTFE |
US5380299A (en) * | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
US5735897A (en) * | 1993-10-19 | 1998-04-07 | Scimed Life Systems, Inc. | Intravascular stent pump |
US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
US5485496A (en) * | 1994-09-22 | 1996-01-16 | Cornell Research Foundation, Inc. | Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties |
US5879713A (en) * | 1994-10-12 | 1999-03-09 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US5869127A (en) * | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US6358556B1 (en) * | 1995-04-19 | 2002-03-19 | Boston Scientific Corporation | Drug release stent coating |
US5865814A (en) * | 1995-06-07 | 1999-02-02 | Medtronic, Inc. | Blood contacting medical device and method |
US20030036794A1 (en) * | 1995-06-07 | 2003-02-20 | Cook Incorporated | Coated implantable medical device |
US5873904A (en) * | 1995-06-07 | 1999-02-23 | Cook Incorporated | Silver implantable medical device |
US20030028244A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US20030028243A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US6010530A (en) * | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US6051648A (en) * | 1995-12-18 | 2000-04-18 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US5723219A (en) * | 1995-12-19 | 1998-03-03 | Talison Research | Plasma deposited film networks |
US6033582A (en) * | 1996-01-22 | 2000-03-07 | Etex Corporation | Surface modification of medical implants |
US5610241A (en) * | 1996-05-07 | 1997-03-11 | Cornell Research Foundation, Inc. | Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers |
US5876433A (en) * | 1996-05-29 | 1999-03-02 | Ethicon, Inc. | Stent and method of varying amounts of heparin coated thereon to control treatment |
US6172167B1 (en) * | 1996-06-28 | 2001-01-09 | Universiteit Twente | Copoly(ester-amides) and copoly(ester-urethanes) |
US5711958A (en) * | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US6338904B1 (en) * | 1996-11-25 | 2002-01-15 | Scimed Life Systems | Polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents |
US6042875A (en) * | 1997-04-30 | 2000-03-28 | Schneider (Usa) Inc. | Drug-releasing coatings for medical devices |
US5879697A (en) * | 1997-04-30 | 1999-03-09 | Schneider Usa Inc | Drug-releasing coatings for medical devices |
US6524347B1 (en) * | 1997-05-28 | 2003-02-25 | Avantis Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6180632B1 (en) * | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6528526B1 (en) * | 1997-05-28 | 2003-03-04 | Aventis Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6034204A (en) * | 1997-08-08 | 2000-03-07 | Basf Aktiengesellschaft | Condensation products of basic amino acids with copolymerizable compounds and a process for their production |
US6015541A (en) * | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US6344035B1 (en) * | 1998-04-27 | 2002-02-05 | Surmodics, Inc. | Bioactive agent release coating |
US20020032434A1 (en) * | 1998-04-27 | 2002-03-14 | Chudzik Stephen J. | Bioactive agent release coating |
US20030031780A1 (en) * | 1998-04-27 | 2003-02-13 | Chudzik Stephen J. | Bioactive agent release coating |
US20020032414A1 (en) * | 1998-08-20 | 2002-03-14 | Ragheb Anthony O. | Coated implantable medical device |
US6335029B1 (en) * | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US6011125A (en) * | 1998-09-25 | 2000-01-04 | General Electric Company | Amide modified polyesters |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6689099B2 (en) * | 1999-07-13 | 2004-02-10 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
US20030040712A1 (en) * | 1999-07-13 | 2003-02-27 | Pinaki Ray | Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway |
US6177523B1 (en) * | 1999-07-14 | 2001-01-23 | Cardiotech International, Inc. | Functionalized polyurethanes |
US6713119B2 (en) * | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US20040029952A1 (en) * | 1999-09-03 | 2004-02-12 | Yung-Ming Chen | Ethylene vinyl alcohol composition and coating |
US6346110B2 (en) * | 1999-10-04 | 2002-02-12 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implantable device |
US6203551B1 (en) * | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US20020009604A1 (en) * | 1999-12-22 | 2002-01-24 | Zamora Paul O. | Plasma-deposited coatings, devices and methods |
US6503954B1 (en) * | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US20020016625A1 (en) * | 2000-05-12 | 2002-02-07 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020005206A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US20020007214A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007215A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007213A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6673385B1 (en) * | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US20040018296A1 (en) * | 2000-05-31 | 2004-01-29 | Daniel Castro | Method for depositing a coating onto a surface of a prosthesis |
US20040047978A1 (en) * | 2000-08-04 | 2004-03-11 | Hossainy Syed F.A. | Composition for coating an implantable prosthesis |
US6503538B1 (en) * | 2000-08-30 | 2003-01-07 | Cornell Research Foundation, Inc. | Elastomeric functional biodegradable copolyester amides and copolyester urethanes |
US6506437B1 (en) * | 2000-10-17 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device having depots formed in a surface thereof |
US6503556B2 (en) * | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US20040047980A1 (en) * | 2000-12-28 | 2004-03-11 | Pacetti Stephen D. | Method of forming a diffusion barrier layer for implantable devices |
US20030032767A1 (en) * | 2001-02-05 | 2003-02-13 | Yasuhiro Tada | High-strength polyester-amide fiber and process for producing the same |
US20030004141A1 (en) * | 2001-03-08 | 2003-01-02 | Brown David L. | Medical devices, compositions and methods for treating vulnerable plaque |
US6712845B2 (en) * | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US20030039689A1 (en) * | 2001-04-26 | 2003-02-27 | Jianbing Chen | Polymer-based, sustained release drug delivery system |
US20040052858A1 (en) * | 2001-05-09 | 2004-03-18 | Wu Steven Z. | Microparticle coated medical device |
US20040052859A1 (en) * | 2001-05-09 | 2004-03-18 | Wu Steven Z. | Microparticle coated medical device |
US6695920B1 (en) * | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US6673154B1 (en) * | 2001-06-28 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Stent mounting device to coat a stent |
US6706013B1 (en) * | 2001-06-29 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Variable length drug delivery catheter |
US6527863B1 (en) * | 2001-06-29 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Support device for a stent and a method of using the same to coat a stent |
US20030060877A1 (en) * | 2001-09-25 | 2003-03-27 | Robert Falotico | Coated medical devices for the treatment of vascular disease |
US20030059520A1 (en) * | 2001-09-27 | 2003-03-27 | Yung-Ming Chen | Apparatus for regulating temperature of a composition and a method of coating implantable devices |
US6709514B1 (en) * | 2001-12-28 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Rotary coating apparatus for coating implantable medical devices |
US20040054104A1 (en) * | 2002-09-05 | 2004-03-18 | Pacetti Stephen D. | Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2450068A1 (en) * | 2009-01-15 | 2012-05-09 | Sungkyunkwan University Foundation For Corporate Collaboration | Bioactive material coating method and tube |
EP2450068A4 (en) * | 2009-01-15 | 2013-12-25 | Univ Sungkyunkwan Found | Bioactive material coating method and tube |
WO2011089624A2 (en) | 2010-01-22 | 2011-07-28 | Concept Medical Research Private Limited | Insertable medical devices with a porous bed for delivering nano-carriers to a target site and methods of preparing the same |
EP2528634A2 (en) * | 2010-01-22 | 2012-12-05 | Concept Medical Research Private Limited | Insertable medical devices with a porous bed for delivering nano-carriers to a target site and methods of preparing the same |
EP2528634A4 (en) * | 2010-01-22 | 2014-04-02 | Concept Medical Res Private Ltd | Insertable medical devices with a porous bed for delivering nano-carriers to a target site and methods of preparing the same |
WO2017049308A1 (en) * | 2015-09-17 | 2017-03-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Biostable segmented elastomers and thermoplastics and methods of making and using thereof |
US10907001B2 (en) | 2015-09-17 | 2021-02-02 | The Arizona Board of Regents on Behlaf of the University of Arizona | Biostable segmented elastomers and thermoplastics and methods of making and using thereof |
WO2022113019A1 (en) * | 2020-11-27 | 2022-06-02 | Uniwersytet Śląski W Katowicach | A membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and the method of obtaining it |
WO2022113015A1 (en) * | 2020-11-27 | 2022-06-02 | Uniwersytet Śląski W Katowicach | Organic material with pore-forming, anti-inflammatory and anticoagulant properties and the method of its preparation |
Also Published As
Publication number | Publication date |
---|---|
US20080132592A1 (en) | 2008-06-05 |
US7807210B1 (en) | 2010-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080125857A1 (en) | Hemocompatible polymers on hydrophobic porous polymers | |
US6833153B1 (en) | Hemocompatible coatings on hydrophobic porous polymers | |
Park et al. | In vitro and in vivo studies of PEO-grafted blood-contacting cardiovascular prostheses | |
Badv et al. | Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants | |
JP6599882B2 (en) | Implantable medical devices | |
ES2326644T3 (en) | FLUOROPOLIMERO COATINGS FOR IMPLANTABLE MEDICAL DEVICES. | |
US6340465B1 (en) | Lubricious coatings for medical devices | |
EP1575631B1 (en) | Coating for implantable devices and a method of forming the same | |
WO2001008718A1 (en) | Universal biocompatible coating platform for medical devices | |
US7390523B2 (en) | Method of forming a diffusion barrier layer for implantable devices | |
Spijker et al. | On the influence of flow conditions and wettability on blood material interactions | |
US6231600B1 (en) | Stents with hybrid coating for medical devices | |
EP1003571B1 (en) | Adherent, flexible hydrogel and medicated coatings | |
CA2866315C (en) | Glycosaminoglycan and synthetic polymer materials for blood-contacting applications | |
EP0964708B1 (en) | Biocompatible lubricious hydrophilic materials for medical devices | |
Klement et al. | Chronic performance of polyurethane catheters covalently coated with ATH complex: a rabbit jugular vein model | |
Kim et al. | Tissue response to poly (L-lactic acid)-based blend with phospholipid polymer for biodegradable cardiovascular stents | |
Sefton et al. | Appendix E–Chapter II. 5.2–Nonthrombogenic Treatments and Strategies | |
WO2002058753A9 (en) | Coating for implantable devices and a method of forming the same | |
Duta et al. | Surface modification of poly (vinylchloride) for manufacturing advanced catheters | |
US6521283B1 (en) | Non-thrombogenic surfaces | |
CN111867647B (en) | Improvements in methods for immobilizing biological materials | |
JP4347927B2 (en) | Method for producing antithrombotic medical device | |
US10266684B2 (en) | Glycosaminoglycan and synthetic polymer materials for blood-contacting applications | |
RU2354409C2 (en) | Method of manufacturing medication-releasing medical devices and device obtained with its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT CARDIOVASCULAR SYSTEMS INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROORDA, WOUTER E.;SHAH, NIRAJ;LUNDKVIST, ANDRE-JEAN;REEL/FRAME:020466/0552;SIGNING DATES FROM 20040409 TO 20040901 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |